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1. Introduction 
 
1.1 Promoter CpG island hypermethylation and gene expression 
 
Approximately 50% of mammalian gene promoters are associated with one or more CpG 
islands (Ioshikhes and Zhang, 2000).  
Clusters of CpG dinucleotides or “CpG islands” (Gardiner-Garden M. and Frommer M., 
1987) are present in the promoter and exonic regions of approximately to 50% of mammalian 
genes.  
 
By contrast, other regions of the mammalian genome contain few CpG dinucleotides and 
these are largely methylated (Larsen et al., 1992). The decreased occurrence of CpG is best 
explained by the fact that methylated cytosines are mutational hotspots leading to CpG 
depletion (Coulondre et al., 1978). A large number of experiments have shown that 
methylation of promoter CpG islands plays an important role in gene silencing (Bird, 2002), 
genomic imprinting, X-chromosome inactivation, the silencing of intragenomic parasites, and 
carcinogenesis (Baylin et al., 1998).  
 
The extent of aberrant promoter hypermethylation and its association with loss of gene 
function in cancer suggests that CpG island methylation is an important mechanism in 
inactivating tumor suppressor genes (TSGs) (Narayan et al., 2003). 
 
For tumor suppressor genes, promoter hypermethylation is very important and can change 
alone ever designate true tumor suppressor gene function (Baylin at al., 2001). Aberrant 
promoter methylation changes that occur in cancer are associated with transcriptional 
repression and loss of function of the gene by interrupting the binding of proteins involved in 
transcription activator complex (Jones and Baylin, 2002). There are a lot of the genes which 
are affected by promoter CpG island methylation in aging and / or cancer such as BRCA1, 
HIC1, MYOD1, p57, PAX6, WT1. 
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1.2 POZ-Zincfinger Proteins 
 
The C2H2 zinc finger domain defines a family of genes that has been expanded independently 
in each of the major eukaryotic lineages including yeast, worm, fly, and human (Lander et al., 
2001 and Venter et al., 2001). In humans, the result of the expansion has been remarkable, in 
that more than 700 C2H2 zinc finger domain-containing genes are predicted to exist, making it  
the second most populous family in the human genome (Lander et al., 2001). The C2H2 zinc 
finger is a small peptide domain with a secondary structure stabilized by a zinc ion bound to 
the conserved cysteine and histidine residues of the finger (Pavletich and Pabo, 1991). The    
primary role of these regulators is to bind to specific DNA segments via their zinc fingers and    
interact with other cellular factors to control the transcription of target genes. Such conserved 
modules found at the N-terminus of C2H2 zinc finger transcription factors include the 
BTB/POZ (Broad-Complex, Tramtrack, and Bric-a-brac/poxvirus and Zinc finger) (Bardwell 
and Treisman, 1994). 
The C2H2 zinc fingers represent one of the most common types of DNA-binding domains. 
This large family of transcription factors can be further divided in to functional subclasses 
sharing a divergent and highly conserved module (Collins et al., 2001). One such module is 
the BTB/POZ (for bric a brac, tramtrack, Broad-Complex/poxviruses and zinc fingers ) 
domain an approximately 120 amino acid domain identified in various species from yeast to 
human. It occurs at the N-terminus of developmentally regulated transcription factors 
containing C2H2 zinc fingers as well as in actin-binding proteins (Bardwell 1994; Albagli et 
al.,1995). The BTB/POZ domain has even been found in a new subfamily of Rho proteins 
conserved from Dictyostelium to mammals (Dhordain et al., 1995). 
 
The PLZF BTB/POZ domain (Ahmad et al., 1998), encompass most of the residues involved 
in the dimerization of this domain are well conserved. 
The BTB/POZ is an evolutionarily conserved domain found in most organisms, including 
human, mouse, fly, and yeast (Lander et al., 2001 and Venter et al., 2001). This domain is 
capable of mediating homo- and heterodimerization and several BTB/POZ-containing 
proteins silence gene expression by distinct recruitment mechanisms. For example, the 
BTB/POZ-proteins BCL6 (B cell lymphoma) and PLZF (promyelocytic leukemia zinc finger) 
repress transcription by recruiting SMRT (silencing mediator for retinoid and thyroid 
hormone receptors)/N-CoR (nuclear receptor  corepressor)-mSin3A-histone deacetylase 
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complexes (David et al., 1998; Dhordain et al., 1998; Huynh and Bardwell 1998, and Wong 
and Privalsky, 1998), whereas HIC-1 (hypermethylated in cancer) mediates transcriptional  
repression by both histone deacetylase-dependent and independent mechanisms that involve 
binding to the corepressor, CtBP (C-terminal binding    protein) ( Deltour et al., 1999 ; 2002). 
Several human BTB/POZ and C2H2 zinc fingers proteins have been implicated in malignant 
diseases. BC-6 (B-cell lymphoma-6) and PLZF (promyelocytic leukemia zinc finger) are 
implicated in translocations associated respectively with diffuse large cell lymphomas and 
promyelocytic leukemias (Albagli et al., 1995).  
 
How important are zinc finger proteins? 
 Zn fingers proteins seem to regulate central nervous system development, may function 
between DNA-RNA hybrids, and may be oncoproteins in leukemogenesis. BTB proteins are 
transcriptional regulators found at the N-terminus of 5-10% C2H2 Zinc finger. There is a large 
number of human BTB genes which vary in the different number of zinc fingers: PLZF 
(9ZnF), BCL-6 (6ZnF), HIC-1 (5ZnF), MIZ-1 (13ZnF), KIAA0352 (9ZnF), RP58 (4ZnF), 
hcKROX (4ZnF). 
 
 
1.3 HIC1 (Hypermethylated in cancer 1 gene) gene, human HIC2 
homologue  
HIC1 encodes a protein with five Krüppel-like C2H2 zinc fingers in the C terminus and a 
protein-protein interaction domain called the BTB/POZ domain at the N terminus. Many 
proteins with BTB/POZ domains and zinc fingers are transcriptional repressors, such as 
Drosophila Tramtrack and human BCL6 and PLZF, which are associated with translocations 
in some leukemia (Albagli et al., 1995, Bardwell et al., 1994). HIC1 (hypermethylated in 
cancer) is a candidate tumor suppressor gene identified because of its association with a 
“CpG” island at 17p13.3 that is aberrantly hypermethylated and transcriptionaly inactivated in 
several common types of human cancer (Makos-Wales et al., 1995) and lost in the Miller-
Dieker syndrome (Carter et al., 2000).  
HIC1 significantly decreases the clonogenic survival of various cancer cell lines, and its 
expression is up regulated by p53 through a functional p53 binding site in its 5' flanking 
region (Guerardel et al., 2001, Makos-Wales et al., 1995). HIC1 is a transcriptional repressor 
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(Deltour 1999) as is its avian homologue, FBP-B (F1 binding protein B), (Liu et al., 1994). 
Both the HIC1 and FBP-B BTB/POZ domains are autonomous transcriptional repression  
 
domains but, in sharp contrast with those of BCL-6 and PLZF, they are unable to recruit 
SMRT/NCoR-mSin3A-HDAC complexes and are insensitive to trichostatin A (TSA), a 
specific inhibitor of HDACs (Deltour, 1999).  
 
1.4  Hic1 a mouse gene 
The Hic1 gene encodes a zinc-finger protein with a poxvirus and zinc-finger (POZ) domain 
and has been mapped to mouse chromosome 11 in a region exhibiting conserved synteny to 
human chromosome 17. The deduced Hic1 protein consists of 892 amino acids including a 
POZ domain and five C2H2 zinc fingers at the C terminus. During embryonic development, 
Hic1 is expressed in mesenchymes of the sclerotome, lateral body wall, limb and cranio-facial 
regions surrounding the outgrow of peripheral nerves during their differentiation. During fetal 
development, Hic1 additionally is expressed in mesenchymes apposed to precartilaginous 
condensations, at many interfaces to budding epithelia of inner organs, and weakly in 
muscles. 
Activation of Hic1 expression was observed in the embryonic anlagen of many tissues 
displaying anomalies in Miller-Dieker syndrome (MDS) patients (Grimm et al., 
1999).Together with perinatal death and a reduction in overall size, HIC1-/- mouse embryos 
have other developmental anomalies resembling those found in MDS patients (Carter et al., 
2000), and parts of the HIC1 expression territories overlap with regions exhibiting 
abnormalities in MDS patients (Grimm et al., 1999). 
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1.5 HIC2 (Hypermethylated in cancer 2) a Human Homologue of the 
Putative Tumor Suppressor Gene HIC1 
 
By sequencing clones obtained from a size-fractionated fetal brain cDNA library, Kikuno et 
al. (1999) cloned HIC2, which they designated KIAA1020.Deltour et al. (2001) extended the 
sequence of KIAA1020 in the 5-prime direction by comparison with a genomic clone and by 
RT-PCR of a cerebellum cDNA library. The deduced full-length HIC2 protein contains 615  
amino acids. It has an N-terminal BTB/POZ domain, a conserved GLDLSKK/R polypeptide, 
and 5 C-terminal Kruppel-type C2H2 fingers, 4 of which are grouped and are separated by a 
typical 7- to 8-amino acid link. HIC2 shares more than 80% homology with HIC1 through the 
BTB/POZ and zinc finger domains, and both proteins have identical GLDLSKK/R motifs. 
This motif is highly related to the consensus motif PxDLSxK/R firs identified in the C-
terminal part of the E1A protein (Schaeper et al., 1995), later in numerous transcriptional 
repressors in Drosophila (Nibu et al., 1998) and vertebrates (Criqui et al., 1999) able to bind 
to the CtBP (C-terminal Binding Protein) corepressor (Deltour et al., 2002). It encodes a 
hypermethylated in cancer 2 like family member. 
 
By transient transfection in COS7 cells, Deltour et al. (2001) found that HIC2 colocalize with 
HIC1 onto nuclear dots. Their BTB/POZ domains heterodimerize and repressed transcription 
from a reporter plasmid. Inhibitor studies indicated that HIC1 and HIC2 do not recruit HDAC 
(a histone deacetylase) containing complexes. The central GLDLSKK/R motif was found to 
interact with C-terminal-binding protein. The HIC2 gene contains 2 exons and spans about 6.1 
kb. The promoter region contains a putative TATA box. By genomic sequence analysis, the 
HIC2 gene was localised to chromosome 22q11.2. (Deltour et al., 2001). 
 
RT-PCR ELISA revealed highest expression in cerebellum, with intermediate levels in 
several other brain regions; no expression was detected in substantia nigra. In whole tissues, 
expression was highest in liver, followed by heart, brain, lung, kidney, testis, ovary, fetal 
liver, and fetal brain. Little or no expression was detected in skeletal muscle, pancreas, and 
spleen. 
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1.6 γFBP the avian homologue of the HIC1 and HIC2 gene  
Database searches with the murine Hic1 protein sequence revealed similarities to the chicken 
γF-crystallin binding protein (γFBP). Similar to Hic1 and HIC1, γFBP encodes also a protein 
with a POZ domain and five zinc fingers (Grimm et al., 1999). 
γFBP was expressed during lens differentiation and functionally implicated in the regulation 
of the γF-Crystallin (Crygf) gene (Liu et al. 1994). They have isolated three chicken cDNAs 
that encode proteins capable of binding specifically to the Gamma F-1-binding motif. These 
three cDNAs represent differential splicing products from a single gene, γFBP. The protein 
isoforms encoded by two of these cDNAs differ in their ability to modulate the activity of 
promoters containing the gamma F-1-binding motif. Among them, γFBP-B functions as a 
transcriptional repressor in lens cells, and its expression is developmentally regulated during 
lens development, suggesting a role for this isoform in the spatial regulation of γF-crystallin 
gene expression. 
The expression of the different mRNA transcripts is differentially regulated in various tissues. 
The three distinct cDNAs presumably correspond to differentially spliced products of a single 
gene, since the original cDNA isolated. (Liu et al. 1994). 
 Isoforms are in a tissue-specific maner : γFBP-A highly in kidney and lung, γFBP-B higher in 
the lens, retina, stomach, extremely low in heart, muscle and lung, γFBP-C weakly in heart, 
kidney and lens. 
 Also is known the case of HIC1 and γFBP-B, HIC1 appears unique because it contains a 13-
aa insertion acquired late in evolution, because it is not found in its avian homologue, γFBP-
B, a transcriptional repressor of the γF-crystallin gene. This insertion, located in a conserved 
region involved in the dimerization and scaffolding of the BTB/POZ domain, mainly affects 
slightly the ability of the HIC1 and γFBP-B to homo- and heterodimerize in vivo, both the 
HIC1 and γFBP-B domains behave as autonomous transcriptional repression domains 
(Deltour et al., 1999). During somatic differentiation, FBP expression becomes restricted to 
the sclerotome (Liu et al., 1994).   
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1.7 HIC1 and the Miller-Dieker syndrome 
Most genetic disorders are the result of a mutation in a single gene. However, one of the most 
difficult problems ahead is to find out how genes contribute to diseases that have a complex 
pattern of inheritance, such as in the cases of diabetes, asthma, cancer and mental illness. 
Grimm et al., 1999, observed activation of mouse Hic1 expression in the embryonic anlagen 
of many tissues displaying anomalies in Miller-Dieker syndrome (MDS) patients. Besides 
lissencephaly, MDS patients exhibit facial dysmorphism and frequently additional birth 
defects, e.g., anomalies of the heart, kidney, gastrointestinal tract, and the limbs.  
Thus, HIC1 activity may correlate with the defective development of the nose, jaws, 
extremities, gastrointestinal tract, and kidney in MDS patients. The location of HIC1 in the 
Miller-Dieker syndrome critical deletion region on 17p13.3 makes it a candidate gene for 
involvement in the MDS gene deletion syndrome. 
 To study the function of murine Hic1 in development, Carter et al., 2000, created Hic1-
deficient mice. They found that these animals died perinatal and exhibited varying 
combinations of gross developmental defects throughout the second half of development, 
including acrania, exencephaly, cleft palate, limb anomalies, and omphalocele. These 
abnormalities demonstrated a role for Hic1 in the development of structures affected in the 
Miller-Dieker syndrome, and provided functional evidence to strengthen its candidacy as a 
gene involved in that disorder.  
 
1.8 Gene map locus 22q11.21 
 
There are some of interesting genetic disorders which are located on the human chromosome 
22, near the location of the HIC2 gene. One of them is 22q11 deletion and chronic myeloid 
leukemia. 
 22q11 deletion is associated with Velo-Cardio-Facial Syndrome (VCFS, Sprintzen 
Syndrome), DiGeorge Sequence, CATCH 22, Conotruncal Anomaly Face syndrome (CAFS) 
(Japan) and sometimes seen in Opitz G/BBB syndrome, CHARGE Association and Cayler-
Cardio-Facial Syndrome. 
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Findings provide evidence that people with a 22q11 deletion have disrupted brain 
development which may involve abnormal neural crest cell migration, (Van Amelsvoort et al., 
2001). 
Velo-cardio-facial syndrome (VCFS) is a common genetic disorder associated with variably 
sized deletions at chromosome 22q11 (Scambler et al., 1992). Characteristic physical features 
include cleft lip and/or palate, coronotruncal heart defects, ear anomalies and facial features 
such as a prominent nasal bridge (Shprintzen et al., 1978). Neurodevelopment abnormalities 
include dysarthric speech and ocular abnormalities, (Golding-Kushner et al, 1985; Mansour et 
al, 1987; Swillen et al, 1997). Qualitative neuroimaging studies in VCFS reported cerebellar 
atrophy, agenesis of the corpus callosum, white matter hyperintensities (WMHIs), cavum 
septum pellucidum/vergae and cerebral atrophy (Mitnick et al., 1994; Lynch et al., 1995; 
Chow et al., 1999). 22q11- presents several features, some of these may include: eye 
problems, scoliosis, low muscle tone, microcephaly, cleft palate, immune system problems, 
gastro-intestinal problems. 
 
Chronic myeloid leukemia is fundamentally a genetic disorder, specifically a somatic cell 
genetic disorder, which has environmental causes such as irradiation and chemical (e.g., 
benzene) exposure (Jacobs, 1989).  
Prakash and Yunis (1984) located the breakpoints in CML to subbands 22q11.21 and 9q34.1. 
Although the position of the breakpoint in chromosome 9 is quite variable, the breakpoint in 
chromosome 22 is clustered in an area called bcr for breakpoint cluster region. 
Deletion on chromosome 22q11 is associated with brain abnormalities that are most likely 
neurodevelopment (Van Amelsvoort et al., 2001) 
 
1.9 Tumor suppressor gene 
 
A tumor suppressor gene is a gene that reduces the probability that a cell in a multicellular 
organism will turn into a tumor cell. A mutation or deletion of such a gene will increase the 
probability of a tumor. Tumor suppressor genes, or more precisely, the proteins they code for, 
have a dampening or repressive effect on the regulation of the cell cycle.  
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This is basically done by the tumor suppression genes/proteins in three ways: 
1. Repression of genes they are essential for continuing of the cell cycle. If these genes 
are not expressed, the cell cycle will not continue, effectively inhibiting cell division.  
2. Coupling the cell cycle to DNA damage. As long as there is damaged DNA in the cell, 
it should not divide. If the damage can be repaired, the cell cycle can continue.  
3. If the damage can not be repaired, the cell should initiate apoptosis, the programmed 
cell death, to remove the threat it poses for the greater good of the organism.  
The first tumor suppressor protein discovered was the pRb protein in human retinoblastoma. 
An important tumor suppressor is the p53 gene (Wikipedia, the free encyclopedia). 
  
Tumor suppressor gene protein product inhibits mitosis. They behave as recessives; that is, as 
long as the cell contains one normal allele, tumor suppression continues. (Oncogenes, by 
contrast, behave as dominants; one defective allele can predispose the cell to tumor 
formation). Because tumor suppressor genes are recessive, cells that contain one normal and 
one mutated gene that is, are heterozygous still behave normally. However, there are several 
mechanisms which can cause a cell to lose its normal gene and thus be predisposed to develop 
into a tumor. 
 All of these result in a "loss of heterozygosity" or "LOH". Mechanisms of LOH:  
1. Deletion of the normal allele; the chromosome arm containing the normal allele; the 
entire chromosome containing the normal allele (resulting in aneuploidy). 
2. Loss of the chromosome containing the normal allele followed by duplication of the 
chromosome containing the mutated allele.  
3. Mitotic recombination.  
4. Gene conversion 
Kimball's Biology Pages http://users.rcn.com/jkimball.ma.ultranet/BiologyPages 
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Tumor suppressor genes normally function to inhibit the cell growth and to prevent the 
development of tumors. Some tumor suppressor genes are localized on human chromosome 
22:  
EP300, involved with some colorectal, breast and pancreatic cancers, located on 22q13.2, 
NF2- neurofibromatosis type 2 genes, involved in bilateral acoustic neuromas, meningiomas, 
schwannomas, located on 22q12.2, SMARCB1, involved with malignant rhabdoid tumors, 
located on 22q11.23 
 
P53 is the prototypic tumor suppressor gene that is well suited as a molecular link between 
the causes of cancer, i.e., carcinogenic chemical and physical agents and certain viruses, and 
the development of clinical cancer. The p53 tumor suppressor gene is mutated in the majority 
of human cancers. Genetic analysis of human cancer is providing clues to the etiology of 
these diverse tumors and to the functions of the p53 gene. Some of the mutations in the p53 
gene reject endogenous causes of cancer, whereas others are characteristic of carcinogens 
found in our environment (Curtis H. 1996). The p53 gene activity stops the formation of 
tumors. Mutations in p53 are found in most tumor types. In the cell, p53 protein binds DNA, 
which in turn stimulates another gene to produce a protein called p21 that interacts with a cell 
division-stimulating protein (cdk2). A function of the tumor suppressor p53 becomes evident 
when the gene is mutated or has been eliminated. Gene p53 is highly conserved and present in 
“normal” mammalian cells and moreover, even in cells of birds, fishes and amphibian, (Hess 
and Brander, 1996). 
 
The Wilms tumor suppressor gene WT1 is implicated in the ontogeny of genito-urinary 
abnormalities, including Denys-Drash syndrome and Wilms tumor of the kidney. WT1 
encodes Krüppel-type zinc finger proteins that can regulate the expression of several growth-
related genes, apparently by binding to specific DNA sites located within 5’ untranslated 
leader regions as well as 5’ promoter sequences. WT1 like the Krüppel–type zinc finger 
protein TFIIIA, regulate gene expression by both transcriptional and posttranscriptional 
mechanisms (Caricasole et al., 1996). Expression of the Wilms’ tumor gene Wt1 in the 
epicardium is critical for normal heart development and has a role in the growth of coronary 
vessels after myocardial infarction (Scholz et al., 2003, Abstract). WT1 was detected in more 
advanced estrogenreceptor-negative tumors. In this highly malignant subset, the tumor 
suppressor protein p53, which can physically interact with WT1, was also sometimes 
detected. Alternative splicing of the WT1 mRNA may regulate gene targeting of the WT1 
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protein through changes either in its regulatory or zinc-finger domains (Silberstein et al., 
1997). The Wilms’ tumor gene Wt1 is known for its important functions during genitourinary  
and mesothelial formation. Wt1 is necessary for neuronal development in the vertebrate retina 
(Wagner et al., 2002). 
 
HIC1 (hypermethylated in cancer 1) a candidate tumor suppressor gene is hypermethylated 
and silenced in a large number of solid tumors and his methylation seems to be a progression 
event in hematopoetic neoplasms (Issa J.P. et al., 1997). HIC1 is a candidate tumor suppressor 
gene since it significantly decreases the clonogenic survival of various cancer cell lines, and 
its expression is up regulated by p53 through a functional p53 binding site in its 5’  
flanking region (Guerardel et al., 2001 and Makos-Wales et al., 1995). Chen et al., (2003) 
showed that mice disrupted in the germline for only 1 allele of Hic1 developed many different 
spontaneous malignant tumors, including a predominance of epithelial cancers in males and 
lymphomas and sarcomas in females. Complete loss of Hic1 function in the heterozygous 
mice seemed to involve dense methylation of the promoter of the remaining wild type allele. 
They concluded that HIC1 is a candidate tumor suppressor gene for which loss of function in 
both mouse and human cancers is associated only with epigenetic modifications. 
 
 
1.10 Aim of the work 
 
The aim of this work was the characterization of the Hic2 gene; partial isolation, localization, 
promoter analysis and embryonic expression of the novel mouse gene Hic2, the homologue of 
humane gene HIC2, a candidate for tumor suppressor gene and a way to represent the effect 
of the outcome of results to science following an animal model, which could give a more light 
in mechanism of some human diseases.  
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2 Materials and Methods 
 
2.1 Materials 
There were next tools and materials used: 
2.1.1 Products   
 
Table 2.1: Tools                                             
Tools        Producer 
Agarose-Gelelectrophoresis     GIBCO BRL, Karlsruhe, Germany 
Analysis balance      Chyo balance Corp, Japan 
Analysis balance (Mettler PL 1200)    Utting, Germany 
Bacterial incubator      WT-Binder, Bottmingen, Schweiz 
Bacterial shaker      Infors, München, Germany 
Bio photometer      Eppendorf, Hamburg, Germany 
Cell culture incubator      Heraeus, Hanau, Germany 
Cell culture sterile desk     Gelaire, Opera, Italy 
Refrigerated centrifuge (Universal 16R)   Hettich, Tuttlingen, Germany 
Refrigerated centrifuge (Sorvall RC-5B)   Sorvall, Bad Homburg, Germany 
Electrophoresis power supply (ST 304)   Gibco, BRL, France 
Hybridisation oven      Hybaid, United Kingdom 
Incubator (WTE Binder)     Tuttingen, Germany 
Light microscope (Axiolab)     Zeiss, Oberkochen, Germany 
Light microscope (Axiovert 35)    Zeiss, Oberkochen, Germany 
Light microscope (Axioplan 2)    Zeiss, Oberkochen, Germany 
Light microscope (Orthoplan)    Leitz, Wetzlar, Germany 
Luminometer (Autolumat LB953)    Berthold, Bundoora, Australia 
Microtome (Jung RM 2055)     Leica, Nussloch, Germany 
PCR-thermal cycler (Omnigene)    Hybaid, United Kingdom 
PCR- thermal cycler (PTC-225)    Biozym, Germany 
PCR- thermal cycler (Perkin Elmer 9600)   Norwalh, USA 
PCR- thermal cycler (T3)     Biometra, Germany 
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Table 2.1: Tools 
Tools        Producer 
pH-Meter (Calimatic 5436)     Bachhofer, Germany 
Shaker-incubator (CH-4103)     Bottmingen, Germany  
Spectrophotometer (UltrospecIII®)    Amersham, Germany 
Stereo microscope (Stemi SVII)    Zeiss, Oberkochen, Germany 
Stereo microscope (MZ6)     Leica, Beinsheim, Germany 
Stereo microscope (MZ APO)    Leica, Beinsheim, Germany 
Thermo mixer (5436)      Eppendorf, Hamburg, Germany 
Thermostat 5320      Eppendorf, Hamburg, Germany 
Vortex-2genie       Scientific Industries USA 
     
 
                              
Table 2.2: Cell culture material 
Cell culture material                                                                      Producer 
10 cm Tissue Culture Plate      Becton Dickinson, Heidelberg 
6 cm   Tissue Culture Plate     Becton Dickinson, Heidelberg 
22 mm Tissue Culture Plate (12 wells)   Becton Dickinson, Heidelberg 
15 mm Tissue Culture Plate (24 wells)   Nunc, Wiesbaden 
15 ml Tubes       Nunc, Wiesbaden 
50 ml Tubes       Nunc, Wiesbaden 
2 ml Collection tube      Eppendorf, Hamburg 
1, 5 ml Collection tube     Eppendorf, Hamburg 
 
In all cell culture experiment was used HEK-293 (human, embryonic, kidney) cell line. 
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Table 2.3: Bacterial strains 
Strain                                              genetic back ground 
 
DH5α   deoR, endA1, gyrA96, hsdR17 (r –k m +k), recA1, supE44, thi-1,  
        ∆(lacZY A-argFV169), Φ80δlacZ∆M15; (Stratagene)         
            
                                                                                          
TopF10’ F’ ( lacIq,  Tn 10 (tetr ) ), mcrA, ∆(mrr-hsdRMS-mcrCB)Φ80lacZ ∆M15, 
∆lacX74, deoR, recA1, araD139, ∆(ara-leu)7696, galU, 
galK, rpsL(Strr ), endA1, nupG; (Invitrogen) 
XL1-Blue MRF’∆(mcrA) 183, ∆(mcrCB-hsdSMR-mrr) 173, endA1, 
supE44, thi-1, recA1, gyrA96, relA1, lac[F’ proAB, laqIqZ∆M15, 
Tn 10 (tetr)]; (Stratagene) 
                               All bacterial strains are from the Lab strains E.coli K12 
 
Table 2.4: Chemicals for cell culture 
Chemicals                                                                               Producer 
Agarose (low and high melt)     Biozym, Hess. Oldendorf 
Ampicilin       Sigma, Deisenhofen, Germany 
DNA Molecular weight standard 3 and 8   MBI Ferments, St.Leon-Rot 
DNA Ladder 1 kb      MBI Ferments, St.Leon-Rot 
dNTP- Set        Pharmacia, Freiburg, Germany 
Dual-LuciferaseTM  Reporter assay System   Promega, Mannheim, Germany 
Dulbecco’s Eagle-medium     GIBCO BRL, Karlsruhe, Germany 
Ethidiumbromide      Peqlab Erlangen, Germany 
Foetal calve serum      GIBCO BRL, Karlsruhe 
Glycogen       Roche, Mannheim, Germany         
IPTG        Peqlab Biotechnologie, Erlangen 
NucleoSpin® Extract 2 in 1     Macherey-Nagel, Düren 
NucleoSpin® Plasmid      Marcherey-Nagel, Düren 
PCR-TOPO Cloning Kit     Invitrogen, Karlsruhe, Germany 
Penicillin/Streptomycin     GIBCO BRL, Karlsruhe, Germany 
Profection Mammalian Transfection Systems  Promega, Mannheim, Germany 
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Quiagen DNA Quick Purification Kit   Quiagen, Hilden, Germany 
Quiagen Plasmid Maxi Kit     Quiagen, Hilden, Germany 
Rapid Ligation Kit      MBI fermentas, St.Leon-Rot 
Trypsin/EDTA (10 X), liquid    GIBCO BRL, Karlsruhe 
X-gal        Peqlab Biotechnologie, Erlangen 
 
 
 
 
Table 2.5: Plasmids  
Plasmid       Producer  
pcDNA3.1       Invitrogen, Karlsruhe 
pCR.II-TOPO       Invitrogen, Karlsruhe 
pRL-SV 40       Promega, Mannheim 
pPLLucII       Y. Kamachi  (see references) 
 
 
 
 
 
Table 2.6: Enzymes 
Enzyme       Producer 
Alkaline Shrimp-Phosphatase    Roche, Mannheim 
Klenow- Fragment      MBI fermentas, St. Leon-Rot 
Proteinase E       Roth, Karlsruhe 
Proteinase K       Roche, Mannheim 
Restrictionsendonucleasen     MBI fermentas, St. Leon-Rot 
T4-Ligase       MBI fermentas, St. Leon-Rot 
Taq-DNA-Polymerase     GIBCO BRL, Karlsruhe 
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Table 2.7: Solutions for cultivating of E.coli 
Solution       Ingredients 
LB-Medium       1%       Bacto-Tryton 
                           0.5%     Bacto-Yeast extracts 
                           1%        NaCl 
                           With NaOH pH to 7.0 and autoclaved 
LB Agar      15 g/l     Difco-Agar 
                     Autoclaved 
 
SOC-Medium      2%         Bacto-Trypton   
                            0.5%       Bacto-Yeast extracts  
                             10 mM     NaCl 
                             2.5 mM   KCl 
X-Gal                  20 mM Glucose (sterile filtrated) 
                            20 mg/ml X-Gal in Dimethylformamide 
               Light protected and stored at –20°C   
IPTG      200mg/ml in water, (sterile filtrated) 
            Stored at –20°C   
Ampicilin     10 mg/ml in water 
Kanamycin     10 mg/ml in water 
 
For selection with antibiotics, was used “Selections medium” with 100 µg/ml Ampicilin or 
Kanamycin. For blue-white selection was added 40 µl X-Gal and 4 µl IPTG 
 
 
Table 2.8: Solutions for agar electrophoresis  
 Solution      Ingredients 
6 X DNA Loading buffer   30%        Glycerol 
                                            0.2%        Bromphenolblue 
                                            0.2%        Xylencyanol 
          Diluted in Tris/HCl (pH 7.5) 
TE-Buffer (Tris/EDTA)   10 mM      Tris/HCl (pH7.0) 
                                         1 mM        EDTA 
5 X TBE (Tris/Broat)    0.45 M       Tris   
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                                     0.45 M       Boric acid 
                                      10 mM        EDTA   
Ethidiumbromide stock solution  10 mg/ml Ethidiumbromide in water 
                               Light protected stored at 4 °C 
 
 
Table 2.9: Solutions for Acrylamide electrophoresis 
Solutions        Ingredients       
Bis-Acrylamide     48.3g Acrylamide  
Or 160 ml of 30% Acrylamide solution 
1.7g Bis-Acrylamide 
Or 85 ml of 2% Bis-Acrylamide solution 
10 x TBE      0.9 M TRIS 
0.9 M Boric acid 
0.25 M EDTA 
75 ml Glycerol 
Solution was filtrated and stored at 4°C 
For 100 ml of stock Bis-Acrylamide solution was added 36 µl of TEMED and 1 ml of 10% 
ammonium perisulfate and polymerised at room temperature for 1 hour. 
 
 
Table 2.10: Composition of FA (formaldehyde) gel buffers 
Buffer                                                                   Ingredients 
10 X FA gel buffer     200 mM 3-[N-morpholino] propanesulfonic acid 
MOPS       
50 mM sodium acetate 
                                                                      10 mM EDTA 
                  pH to 7.0 with NaOH 
1 X FA gel running buffer    100 ml 10 X FA gel buffer 
                                             20 ml 37% formaldehyde 
                                              880 ml DEPC water 
5 X RNA loading buffer   16 µl saturated bromphenol blue solution 
                                            80 µl 500 mM EDTA, pH 8.0 
                                           720 µl 37% formaldehyde 
                                             2 ml 100% glycerol 
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                                             3084 µl formamide 
                                            4 ml 10 X FA gel buffer 
                                            Added DEPC water to 10 ml 
                                    Stored at 4°C 
 
 
Table 2.11: Solutions for transfection 
Solution      Ingredients 
Polyfect      from Quiagen Transfection Kit 
PBS-Buffer, 10X     80 g   NaCl 
11.44 g Na2HPO4 
                                 2 g   KCl 
                                 2 g  KH2PO4  
Dissolved in 1 liter of sterile, deionised water 
The pH of 1X PBS was 7.4   
                                                                                
DMEM Medium    +       5 ml  Penicillin/Streptomycin 
                                +       50 ml  FKS (foethal calf serum) 
DMEM Medium    without serum, proteins and antibiotic  
 
 
 
Table 2.12: Other buffers 
Buffer       Ingredients  
PCR Buffer      100 mM                      Tris/HCl   pH 8.3 
                         15, 17.5 or 20 mM       MgCl2 
                         500 mM                       KCl 
                         0.1 %                           Glycerine 
TEN Buffer      10 mM                         Tris/HCl pH 7.5 
                         1 mM                           EDTA 
                         0.1 N                            NaOH 
1% SDS      1 g                                in 100 ml water 
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Table 2.13: Chemicals for Northern Blot 
 
Solution                                                                                  Ingredients 
10 x MOPS        0.4 M Morpholinopropanesulfonic acid     
0.1 M Na-acetate-3 x H2O 
10 mM EDTA 
pH adjusted to 7.2 with NaOH; stored dark in fridge 
[500 ml: 41.9 g MOPS, 6.8 g NaAc, 10 ml 0.5 M EDTA] 
 
Loading Buffer     1 x MOPS 
18.5 % Formaldehyde 
50 % Formamide 
4 % Ficoll400 
Bromphenolblue 
 
[For 1 ml of loading buffer : 100 µl 10 x MOPS, 500 µl Formamide, 185 µl Formaldehyde, 40 
mg Ficoll400, Bromphenolblue, 215 µl H2O] 
Prehybridization-buffer    5 x SSC 
50 % Formamide 
5 x Denhardt's-1 % SDS 
100 µg/ml Salmon sperm DNA  
[For 100 ml of prehybridization buffer: 25 ml 20 x SSC, 50 ml Formamide, 5 ml 100 x 
Denhardt's, 1 g SDS, 1 ml 10 mg/ml DNA]       
      
Hybridization-buffer 
Prehybridization buffer with 5 % Dextransulphate (Na-salt, MW 500,000, 50 % stock-
solution) and without non-homologous DNA 
100 x Denhardt's solution for 500 ml  10 g Ficoll 400 
10 g polyvinylpyrrolidone MW 360000 
10 g BSA fraction 
20 x SSC      3 M NaCl 
0.3 M Na-citrate  
[For 1 l of 20x SSC: 175.3 g NaCl, 88.2 g NaCitrate] 
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Strip-solution      5 mM Tris/HCl pH 8 
0.2 mM EDTA 
0.05 % Na-pyrophosphate 
0.1 X Denhardt's solution 
[500 ml: 2.5 ml 1 M Tris, 200 µl 0.5 M EDTA, 5 ml 5 % NaPP, 1 ml 50 x Denhardt's] 
 
 
Table 2.14: Buffer solutions for Midi DNA isolation (Commercial) 
Buffer       Intergradient 
 
S1:     50 mM Tris/HCl, 10 mM EDTA, 100 µg Rnase A / ml, pH 8.0 
S2:     200 mM NaOH, 1% SDS 
S3:     2.80 M Kac, pH 5.1 
N2:     100 mM Tris, 15%EtOH and 900 mM KCl  
Adjusted with H3PO4 to pH 6.3, 0.15% Triton X-100 
N3: Tris, 15% EtOH and 1150 mM KCl adjusted with H3PO4 to pH 
6.3 
N5:    100mM Tris, 15% EtOH and 1000 mM KCl adjusted to pH 8.5  
 
Table 2.15: Solutions for Mouse Tail Genomic DNA isolation 
Solution    End concentration    Stock 
TNE     10 mM Tris pH 8.0    1    M 
(Tris/NaCl/EDTA)   100 mM NaCl     5    M 
            1 mM EDTA     0.5 M                               
SDS     1 %      10 % 
Proteinase K    10 mg/ml     100 mg/ml 
Protease E    10 mg/ml     100 mg/ml 
Phenol/Chloroform/Isoamylalc. 25:24:1    BIMOL, Hamburg 
TE     10 mM Tris pH 8.0    1 M 
         1 mM EDTA     0.5 M 
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Table 2.16: Chemicals for RNA probes 
Chemicals       Producer   
DEPC (Diethyl Pyrocarbonate)    Sigma, St. Louis, USA 
DIG RNA Labelling Mix     Roche, Mannheim, Germany 
DNAse RNase free      Roche, Mannheim, Germany  
RNAse Inhibitor      MBI fermentas, Vilnius Lithuania 
RNA polymerase SP6     Roche, Mannheim, Germany 
RNA polymerase T3      Roche, Mannheim, Germany  
RNA polymerase T7      Roche, Mannheim, Germany 
t RNA, (10 µg/µl)      Roche, Mannheim, Germany 
 
All solutions used before and for hybridization were absolutely RNAse-free, used DEPC-H2O 
for preparation of RNA-se free solutions, autoclaved for 60 min; DEPC treatment of Tris 
buffer was twice autoclaved. 
 
 
Table 2.17: Solutions for in situ hybridisation 
Solution      Ingredients 
DEPC-H2O      0.01% DEPC (50 µl/500 ml)  
PBS (Phosphate-Buffered Saline)   30 ml NaCl 5M 
              15 ml Na-Phosphate Buffer 1M, pH 7.3 
                Added to 1l with DEPC water 
4% PFA/PBS      4 g PFA (Para formaldehyde) 
                            100 ml DEPC/PBS 
A few drops NaOH 10N; adjusted pH to 6-7 with HCl, used indicator paper 
PBT       PBS 
              0.1% Tween 20 
tRNA       10 µg/µl in DEPC water 
               Phenolized 2 x and stored as aliquots at –20°C 
Proteinase K      2 or 20 µg/ml in Proteinase K Buffer 
Proteinase K Buffer      10ml 1M Tris/HCl pH 7 
                                    1ml 0.5 M EDTA 
       Added to 0.5 l with water 
22 
PBT/Glycine       PBS 
                           Glycine 2 mg/ml 
RIPA       2.5 ml SDS 10% 
                15 ml NaCl 5 M 
                5 ml NP40 
                25 ml Deoxycholate 10% 
                1 ml EDTA 0.5 M 
                  25 ml 1 M Tris/HCl pH 8.0 
                Added to 500 ml DEPC water 
4%PFA/0.2% glutaraldehyde/ PBT   4%PFA/PBT pH 6-7 
                                                   400 µl glutaraldehyde 25% 
                      Adjusted pH to 6-7 with HCl 
                                                   Added to 50 ml PBT 
Deionised formamide, (Roth) 
20 x SSC      17.53 g NaCl 
                       8.82 g sodium citrate 
                     Dissolved in 80 ml DEPC water 
              Adjusted to pH 7 with HCl 
                  Adjusted to 100 ml and autoclaved 
Heparin (Sigma)     100 mg/ml in 4 x SSC DEPC 
Citric acid       1 M in DEPC water 
Hybridisation buffer     5 ml Deionised formamide 
                          2.5 ml 20 x SSC 
                          5 µl heparin 
                            10 µl Tween20 
                                      2.5 ml DEPC water 
        Adjusted to pH6 with 1 M citric acid 
SSC/Formamide/Tween20    5 ml 20 x SSC 
                                               25 ml FA 
                                               50 µl Tween20 
              Added to 50 ml with water 
10 x TBS (Tris buffered saline)   8 g NaCl 
        
                           0.2 g KCl 
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                   25 ml Tris 1 M, pH 7.5 
        Added to 100 ml with water 
TBST        added 0.1% Tween20 to aliquot before use 
Rnase A Buffer     1ml NaCl 5 M 
                                 100 µl Tris HCl 1 M, pH 7.5 
                                 10 µl Tween20 
                                     8.89 ml water 
RNase A (Sigma)     Dissolve RNA-se A at a conc. of 10  
µg /µl in 0.01 M NaAc pH 5.2 
Heated to 100°C for 15 min.; Cooled slowly at RT 
         Adjusted pH by adding 0.1 volumes of 1 M Tris/HCl pH 7.4 
         Stored as aliquots at –20°C 
MAB (Maleic acid buffer)    11.6 g maleic acid 0.1 M 
                 8.8 g NaCl 0.15 M 
Added 800 ml water 
Adjusted with solid NaOH to pH 7.5 
Added water to 1l 
MABT       MAB + 0.1%Tween20 
 
 
Blocking stock solution 
Blocking reagent (Roche) was dissolved in MAB to a final concentration of 10% with shaking 
and heating either on a heating block or in a microwave oven. This stock solution is 
autoclaved and stored as aliquots at –20°C subsequently or at 4°C, add 0,1%Tw20 on day of 
usage 
Dig Antibodies coupled to AP   (Roche) 
TBST*/Levamisol     TBST 
                                2 mM Levamisol 
*Tris buffered saline-Tween20 
Alkaline Phosphatase Buffer    1 ml NaCl 5M 
                                             2.5 ml MgCl 1M 
                                          50 µl Tween20 
                                             5 ml Tris 1M, pH 9.5 
                                             To 50 ml with water 
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Staining solution 
BM purple AP substrate    Added 2 mM Levamisole 
                                         Added 0.5-1% Tween20 
      Centrifuged, pellet was not used 
 
For embedding of the embryos Histowax (Cambridge Instruments, Nussloch) was used. 
Paraffin sections of embryos were mounted on SuperFrost® Plus Microscope Slides, 
(precleaned, ready to use). BM Purple was used to stain paraffin sections and whole embryos. 
After staining, the slides were embedded with Kaiser’s Glycerol gelatine (Merck) and          
covered with Cover glasses from Marienfeld, Germany 
Table 2.18: Primers list 
Name    Sequens        Lab number   
BACTL l*   5‘- GGCTGTATTCCCCTCCATCGTGG- 3‘  XO32599 
BACTL r*  5‘- GCTCATTGTAGAAGGTGTGGTGCCAG- 3‘ XO32599 
Hic2-3.1  5‘- CCACCATGTTCAGTGAGCAAGGAAG - 3‘  29340 
Hic2-5.1  5‘- AAGGTCTGAAGTTTCAGAGGGTGGAGG - 3‘ 29339 
Hic2-Seq1  5‘- CCTGTCCCCAGTCCCTTCAC - 3‘   32415 
Hic2-Seq2  5‘- ACGCATGTGCTCTGTGAGGCGGTAC - 3‘  32633  
Hic2-seq3  5‘- TGGCAGGAACCCTTAGATCCTGTGGC - 3‘ 32634   
Hic2kleinT3-1 5‘- TGAGCCCACTGAGGTTCCACACTC - 3‘  33006 
Hic2-511-R1  5‘- ATACGATGCACTGGGGCCACC - 3‘   33007 
F08seq1  5‘- CCAGCCACATGCGGCAACAC - 3‘   33854 
F08seq2  5‘- CTCTGACACATGCAGCTCCCGG - 3‘  33855      
F08seq3  5‘- GGAGCTGCATGTGTCAGAGGTT - 3‘  33985 
F08seq4  5‘- ATCGGAGGACCGAAGGAGCTAA - 3‘  34159 
F08seq5  5‘- CCGATCAGCCAAACGTCTCTTC - 3‘  34296 
F08seq6   5‘- CGTCCTCAAGCTGCTCTTGTG - 3‘    34445 
F08seq7  5‘- CCACTTAAACCGTATAGCCAACAA - 3‘  34576  
Hic2-F16-ns  5‘- CTTCAGTTTGCGGCGACAGAGG - 3‘  35645   
Hic2-klns-2  5‘- ACCCTGCCGCTTACCGGATAC - 3‘   36182 
F16-07-n  5‘- TCGAGCCTGGATGACAGAGGC - 3‘  36623 
F16-45-n  5‘- GACCGTGTCCTCTCATTTCCTGC - 3‘  36624 
Neu_seq  5‘– TCTGATTCCCAGGATCTGATGCC – 3‘  37039 
F16-45-n1  5‘– GACCGTGCCTCTCATTTCCTGCC – 3‘  37040 
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F16-45-n2  5‘- GACCGTGCTCTCTCATTTCCTGCC- 3‘  37353 
Hic2-NB-3  5‘- TGCACTGCAAAGACACAAGCACAC- 3‘  37400 
Hic2-NB-5  5‘- GCCAAAGACCCGTGGGAGC - 3‘   37401 
Hic2-ISS1-3  5‘- GGCCCAGAGGGCTCTTTAGTTGC - 3‘  37402 
Hic2-ISS2-3  5‘- CACGAGAGCAAGAGTACCGATGGC - 3‘  37404 
Hic2-ISS2-5  5‘- GGAACAGTCAGGGTGACCCATTG - 3‘  37403 
Hic2-F16-ns3  5‘- TGGCCCACAACCTCTGTTCTATCC- 3‘  37473 
PCR-ns-n  5‘– GGCACCACCTGTGGGCA- 3‘   37571  
PCR-ns-c  5‘- AGGTTCTCTTTGTGACCTCTGACC - 3‘  37572  
Hic2-ns‘-4  5‘- GAGACAGGATCTCCCTTTGGAACC - 3‘  38091  
Hic2ML                      5’- CAGGTATGAAAGAAGTCATTCACAG - 3’  40713 
Hic2MR                      5’- TTAGGTATTTAGCTCATTTACATTTCC – 3’ 40714 
EX-2- L  5‘- ATGGAGCTTCCCAGCCA- 3‘    41914 
EX-2-R1  5‘- TGAACTTGCCTCCACAGAGC - 3‘   41915 
EX-2-R2  5‘- CTGCTCCAGGCACCACTT - 3‘   41916 
EX-2-L-1  5‘- AGCACTCTACTCACTGCTGCC -3‘   41957 
EX-2-L-2  5‘- GTGCTGGTGGAGGTGGC - 3‘   41958      
EX-2-R-1  5‘- CAGGCAGGGCTCAGAATC- 3‘   41959 
Son1-R  5‘- CCACTACTCCCATTGGTGCTGG- 3‘   42030  
Son1-L  5‘– GCAAACTGAAGCGAGCTGGC - 3‘   42029 
Son2-L   5‘- CTGAGTGACAGCCAGCGAGAGTC- 3‘  42031 
Son2-R  5‘- CTCTGCCCACTGTCCTCACTCC- 3‘   42032 
Son3-Ra  5‘- CCACTCTGCCCACTGTCCTCAC - 3‘  42033 
Son3-Rb  5‘- TGAATGCCGGAGGCTCTTGC - 3‘   42034 
IEx1-1D             5’- GCAGCTAGGTGGCATTATGTAG - 3’  44117 
Prom-L-1  5’ – CAGTAGAGGCAGATTGGCTC - 3’   44116 
IEx1-3L  5’- CAGAAGAGCCCTGTTGCC - 3’   42576 
IEx1-5L  5’- CCCTGCTTGTTCCAGGG - 3’    42577 
IEx1-6L  5’- CCAGGTCTGGTCACATTCC - 3’   42579 
IEx1-7L  5’- GAGGTCCTGAAGAACCATGCT - 3’   43773    
The primers were synthesised from UTZ Linzner from the AG BIODV/IEG, GSF or MWG 
BIOTECH AG Company (Ebersberg, Germany). *  MWG number. 
 
 
26 
2.2 Methods 
 
2.2.1 Polymerase Chain Reaction PCR 
2.2.1.1 PCR 
The purpose of a PCR is to make a huge number of pieces of DNA (Don et al., 1991). This is 
necessary to have enough starting template for sequencing or cloning. This was done with an 
automated cycler (Perkin Elmer, Stratagene, Biozym), which heated and cooled the tubes with 
reaction mixture in a very short time. The cycling reactions were: 
1. Denaturation 
2. Annealing 
3. Extension 
Denaturation was done at 94 -95°C for 1-2 minutes. During this step the double strand melts 
to single stranded DNA (all enzymatic reactions were stopped). 
Annealing was done between 49-60°C. Extension was at 72°C, which is an optimal 
temperature for the Taq DNA polymerase and synthesis of double strands. 
Components for PCR-pool were: DNA (2 µl recombinant plasmid DNA, 1µl genomic DNA), 
0.2 mM dNTP, 15-20 mM MgCl2 10 X Taq-Buffer, 1 U Taq-Polymerase in one volume from 
20 µl. It was possible to add some additives like DMSO (2-10%) and Q-solution, especially 
for template DNA with a high GC content. 
 
Cycle    Reaction Time   Temperature  Repeats 
 1     Denaturation           1-2 min                   95°C                     1 X 
 
        Denaturation          0.5-1 min                 95°C 
2      Annealing              0.5-1 min                 49-60°C               35-40 X   
        Extension               0.5-2 min                 72°C 
3  Extension               10-15 min                72°C                      1 X 
 
After PCR, the products were assessed by Agarose gel electrophoresis. Amplification 
products were derived from the gel, extracted and used as samples for sequencing and for 
cloning. 
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2.2.1.2 Reverse transcription-polymerase chain reaction (RT-PCR) 
 
RT-PCR is the sensitive technique for m-RNA detection. The technique consists of two parts: 
1. synthesis of cDNA from RNA by reverse transcription (RT) 
2. amplification of a specific cDNA by polymerase chain reaction (PCR) 
First consideration for synthesis of cDNA was RNA isolation, which should be of high 
quality and free of genomic DNA contamination. RT-PCR begins with reverse transcription 
reaction used an RNA template, primer (random or oligo dT), rNTPs, buffer and a reverse 
transcriptase. 
Generating full-length first-strand cDNA from mRNA was done with Ready To GoTM T-
Primed First-Strand Kit. This kit has been designed to provide all the reagents necessary to 
generate full-length first strand cDNA from mRNA template using an oligo (dT) Primer 
containing a NotI restriction site. For cDNA synthesis it was used about 5 µg of total RNA. 
The sample was brought to a volume of 33µl in RNase-free micro centrifuge tube using 
DEPC-treated water, and heated to 65°C for 5 minutes just like Reaction Mix too. Both were 
transferred to a 37°C for 5 min. RNA solution was transferred to the First strand Reaction 
Mix and was not mixed. It was incubated at 37°C for 5 min and mixed gently and centrifuged 
1 min at 13000 rpm. After was incubated at 37°C for 60 minutes. The completed first-strand 
reaction was ready for PCR amplification. 
RNA was from different tissues and embryonic stages: 9.5, 10.5, 12.5, 13.5, 15.5, 17.5 and 
new born pups. Tissues used were from brain, eye, liver, kidney, retina, heart, and lung. 
Components for RT- PCR-pool were: cDNA 1-2 µl, 0.2 mM dNTP, 17.5-22 mM MgCl2 10 X 
Taq-Buffer, 1 U Taq-Polymerase in one volume from 20 µl. It was added Q-solution. 
 
Cycle    Reaction  Time   Temperature  Repeats 
1    Denaturation  1-2 min                   95°C  1 X 
         Denaturation  0.5-1 min                 95°C 
2   Annealing   0.5-1 min                 56-60°C  35-40 X   
     Extension  0.5-2 min                 72°C 
3   Extension  10-15 min                72°C   1 X 
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After PCR reaction the products were assessed by Agarose gel electrophoresis. Some of them 
were derived from the gel and used as template for probes for RNA In situ hybridisation or for 
cloning in special vector for cDNA. 
2.2.2 Gel Electrophoresis 
 
2.2.2.1 Acrylamide gel electrophoresis 
 
Acrylamide gels were prepared for analysis of PCR and digested products. 
Mixed stock solution containing Acrylamide: Bis-Acrylamide was prepared with 48.3 g of 
Acrylamide or 160 ml of 30% Acrylamide solution, 1.7g of Bis-Acrylamide or 85 ml of 2% 
Bis-Acrylamide solution, 50 ml of 10 x TBE which contained 0.9 M Trizma base, 0.9 M 
Boric acid, 0.25 M EDTA, 75 ml of Glycerol and added water to 500ml. Solution was 
filtrated and stored at 4°C 100ml of the stock solution was taken and 36 µl of TEMED and 
1ml of 10% ammonium perisulfate was added and polymerised at room temperature for 1 
hour between two glass plates. 
In 1 X TBE buffer at 80 V gel was runned about 4 hours.  
 
2.2.2.2 Agarose gel electrophoresis 
Agarose gels were prepared for analysis of PCR and digested products. The gel was 
polymerised at room temperature for 15 minutes. For PCR product extraction small DNA 
Low Melt Agarose was used. Agarose gel was used for test of isolated RNA and prepared In-
situ probes. In that case Ethidiumbromide was added inside, 2 µl in 100 ml gel-pool; voltage 
was 200V for 15-25 minutes.  
 
 
2.2.2.3 Preparation of denaturing- agarose gels (RNA) 
The integrity and size distribution of total RNA was checked by denaturing-agarose gel 
electrophoresis and ethidium bromide staining. 28S and 23S ribosomal RNA bands were 
presented at approximately twice the amounts of the 18S and 16S RNA. Gel was prepared 
with Agarose, and runned in running buffer. RNA sample was prepared with 40µl of RNA 
and 10 µl of 5 X loading buffer. 
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2.2.3 Computer Sequence analysis 
 
For sequences analyses different programs were used 
  
Program     analysis 
Vector NTI     primers 
Contig-express     Contig, new molecules with DNA, cDNA 
NCBI      EST-s analysis 
ORF Finder (NCBI)    open reading frame 
Genescan     exon-intron position 
WEBGENE     CpG islands 
CGAP      virtual northern blot 
SWISSPROT-EURASIP   multiple alignments 
 Sequencing reaction 
ABI 3100 genetic Analyzer for sequencing was used. This Analyser is based on capillary 
electrophoresis and requires careful preparation of sequencing samples for optimum results. 
Template for sequencing was prepared in this order: 
PCR reaction was done with genomic DNA (100 ng/ µl); PCR product was extracted from the 
gel per Macherey-Nagel NucleoSpin extract kit. 
 
Components:    1-2 µl PCR products 
                        1 µl Sequencing-Primer (10pmol/µl) 
                        2 µl Big Dye Kit 
                         5-6 µl water 
                               _______________________________ 
              Completely volume 10 µl 
Cycle                  Reaction                Time            Temperature           Repeats 
1  Denaturation           10 sec                98°C                     1 X 
Denaturation          10 sec                 94°C 
2  Annealing               5 sec                   50°C                      30X   
      Extension               4 min                  60°C 
3  Extension               4 min                  60°C                       1 X 
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Precipitation:              10 µl PCR product 
                                   8 µl water 
                                   32 µl EtOH (RT; 95%) 
Vortexed, leaved for 15 min at RT, centrifuged 15 min at 13000 rpm/min(Rotor 12154-H, 
Sigma 3K18) precipitate twice washed with 100 µl of 70% EtOH, and again twice centrifuged 
for 15 min at 13000 rpm/min. Precipitate dried in speed vac for 20 min. 
For resuspending of template DNA was used DEPC water. 
Pellets eluted in 100 µl HPLC water, 15-20 µl added to ABI 3100 Sequencer 
 
Template   Template quantity    Primer quantity  Total  
PCR product 
100-200bp       1-3 ng     3.2 pmol              12µl 
200-500bp                       3-10 ng                                                      3.2 pmol   12µl 
500-1000bp                     5-20 ng                                                      3.2 pmol   12µl  
 
Almost all templates were sequenced by “Sequisrve” Company from Vaterstetten and some of 
them in the GAC-GSF self-made. 
 
The GSS division of GenBank  
The GSS division of GenBank is similar to the EST division, with the exception that most of 
the sequences are genomic in origin, rather than cDNA (mRNA).  It should be noted that two 
classes (exon trapped products and gene trapped products) may be derived via a cDNA 
intermediate. Care should be taken when analyzing sequences from either of these classes, as 
a splicing event could have occurred and the sequence represented in the record may be 
interrupted when compared to genomic sequence. The GSS division contains (but is not 
limited to) the following types of data: random "single pass read" genome survey sequences, 
cosmid/BAC/YAC end sequences, exon trapped genomic sequences, Alu PCR sequences and 
transposon-tagged sequences. 
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2.2.4 Nucleic Acids Isolation 
2.2.4.1 Mouse Tail Genomic DNA Isolation 
Tail samples (1cm) were placed in 1.5 ml micro centrifuge tube and stored at -80°C to 
minimize cross-contamination. All work was done on the ice. 500 µl TEN buffer, 50 µl 1% 
SDS, 25 µl Pronase E and 7.5 µl Proteinase K were added to the tails, and incubated over 
night at 37°C with mixing. The solid parts were after centrifugation on the bottom, 
supernatant was transferred in a new tube. It was added 500 µl of Phenol-Chloroform-Isoamyl 
Alcohol (PCI, 25:24:1), mixed well by repeted inversion. It was centrifuged at full speed 
(14000 rpm/min) for 5 minutes. Then was transferred the resultant aqueous phase to a fresh 
tube. To Sample –containing tube was added 950 µl 100% EtOH, it was formed a visible 
DNA precipitate which was recovered by lifting the DNA with a yellow pipette tip and partial 
suction from a pipettor, transferred to a 1.5 ml tube containing 70% EtOH. It was centrifuged 
at 14000 rpm/min and dried in speed vac. DNA was resolubilizated in 500 µl TEN buffer and 
stored at -20°C. 
 
2.2.4.2 Plasmid DNA isolation 
Midi DNA preparation was done with Nucleobond ax 100 kit. The bacterial culture was 
centrifuged at 4000 rpm/min for 5 min at 4°C. Pellet was resuspended in 4 ml of buffer S1. It 
was added 4 ml of buffer S2, inverted gently 6-8 times and incubated at room temperature for 
5 min. Then it was added 4 ml buffer S3, gently inverted 6-8 times and incubated on ice for 5 
minutes. Lysate was centrifuged at 14000 rpm/min(R 12154-H, Sigma 3K18) at 4 °C for 25 
minutes. In the mean time cartridges were equilibrated with 2.5 ml buffer N2. Clear lysate 
was loaded onto equilibrated cartridges and washed with 2 x 5 ml of buffer N3. It was eluted 
with 5 ml of buffer N5 and precipitated with 0.7-0.8 volume of isopropanol (3.6 ml), 
centrifuged for 30 min at 14000 rpm/min at 4°C, washed with 70% EtOH, preequilibrated at 
4°C and centrifuged at 14000 rpm/min for 10 minutes at 4°C. The pellet was dried at room 
temperature about 10 minutes, resolubilizated in water and stored at –20°C. 
Mini DNA preparation was done with NucleoSpin Plasmid kit. The bacterial culture was 
centrifuged at 4000 rpm/min for 1min. Supernatant was removed. It was added 250 µl of A1 
buffer, and resuspended by vigorous vortexing. Than it was added 250 µl of A2 buffer and 
inverted 6-8 times, incubated at room temperature for a maximum of 5 minutes, added 300 µl 
of A3 buffer, inverted 6-8 times and centrifuged 10 minutes at 13000 rpm/min at room 
temperature. NucleoSpin® Plasmid column was placed in a 2 ml collecting tube; supernatant  
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was loaded on the column and centrifuged at 13000 rpm/min for 1 min. After it was added 
600 µl of A4 buffer, centrifuged for 1 min at 13000 rpm/min. It was dried wail reinserted 
column into the 2 ml collecting tube, and centrifuged for 2 min at 13000 rpm/min. Finally 
membrane was incubated 1 min at room temperature and diluted in 50 µl of AE buffer during 
the centrifuge for 1 min at 13000 rpm/min. (Stored at 4°C and –20 °C). 
The concentration and quality of a sample of DNA were measured with a UV 
spectrophotometer. A solution contained 50 µg/ml of double strand DNA had an absorbancy 
(optical destiny) of 1.0 at wave length of 260 nm. 
 DNA quality measurement is based on the fact that OD at 260 nm is twice that at 280 nm if 
the solution contains pure DNA. Clean DNA has an OD260/280   between 1.8 and 2.0. 
 
2.2.5 RNA Isolation 
2.2.5.1 Isolation of total RNA from animal tissues with RNeasy® Mini kit 
Different embryos development stages and tissues were used. Embryos were 9.5, 10.5, 12.5, 
13.5, 14.5, 17.5 and tissue was from new born mouse pups: brain, eye, lung, skin, kidney, 
heart. The tissue were prepared sterile from the body, placed in RNase -free tubes and stored 
at dry ice, just like embryos to avoid the Ribonucleases (RNases). Ribonucleases are very 
stable and active enzymes. Since RNases are difficult to inactivate and only minute amounts 
are sufficient to destroy RNA, all plasticware or glassware were used with first eliminating 
possible RNase contamination (autoclaved).  Starting material was up to 20-30 mg. Tissue 
was placed in vessel for homogenizer, 350-600 µl RTL Buffer was added and homogenised 
with homogenizer at room temperature. In RTL Buffer β-ME (2-Mercaptoethanol) was added 
before use (β-ME must be added to buffer RTL and buffer RLC before use. β-ME is toxic. 
RNeasy® Mini Handbook, Second Edition, Qiagen). Lysate was centrifuged for 3 min at 
13000 rpm Supernatant was used and added 1 volume 350-600µl of 70% EtOH to the cleared 
lysate and mixed well by pipetting 700µl of the sample including any precipitate was applied 
in mini spin column sitting in a 2 ml collection tube and centrifuged for 1 min. Flow-trough 
was discarded and added 350µl of RW-1 Buffer then centrifuged 30 seconds at 13000 rpm. 
After it was added DNAse I incubation mix (10µl DNAse I + 70µl RDD Buffer). Incubation 
was at room temperature for 15 min and after was added 350µl RW1 Buffer and centrifuged 
30 sec at 13000 rpm. Column was placed in the new 2-ml collection tube, and washed 2 x 
with 500µl RPE Buffer for 2 min at 13000 rpm. Empty column was placed in the new 
collection tube and centrifuged for 1 min. RNeasy column was transferred into a new 1.5 ml  
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Collection tube and eluted with 30-50µl of Rnase-free water and centrifuged 1 min at 13000 
rpm. This RNA was stored at –80°C, and is stable for a longer time. 
The concentration and purity of RNA was determinate by measuring the absorbency (optical 
density) at 260 nm (A260) and 280 nm (A280). An absorbency of 1 unit at 260 nm corresponds 
to 40 µg of RNA per ml (A260 = 1 = 40 µg/ml). The measurements were in water diluted 
2:198, and purity was given trough the ratio between the absorbency values at 260 and 280 
nm. RNA was checked at 1% agarose gel for 10 min at 200V. 
Calculations involved in RNA quantitation were: 
Volume of RNA sample =100 µl 
Dilution = 10 µl of RNA sample + 490 µl water (1:50) 
A260 = 0.23; measured in water A260 value of 1 was equal to 40 µg/ml of RNA. 
The ratio between the readings taken at 260 nm and 280 nm (A260/ A280) provided an estimate 
of the purity of RNA, ranging from 1.5-1.9 is for different types of water, ratio of 1.8-2.1 for 
10 mM Tris/HCl, and pH 7.5. 
 
2.2.5.2 Isolation of total RNA with RNAzolTM B 
 
Different embryos development stages and tissues were used. Embryos were 9.5, 10.5, 12.5, 
13.5, 14.5 and tissues were from new born mouse pups: brain, eye, lung, skin, kidney, heart. 
The tissue were prepared sterile from the body, putted in RNAse free tubes and stored at dry 
ice, just like embryos to avoid the Ribonucleases (RNases). Ribonucleases are very stable and 
active enzymes. Since RNases are difficult to inactivate and only minute amounts are 
sufficient to destroy RNA, all plasticware or glassware were used with first eliminating 
possible RNase contamination.   Starting material was up to 20-30 mg. Tissue was placed in 
vessel for homogenizer, 100- 500 µl of RNAzolTM solution was added. All steps were done 
on the ice. 1/10 volume of the Chloroform was added, 15 sec vortexed and 15 min incubated 
on ice, centrifuged for 15 min 13000 rpm at 4°C. Supernatant stored in new Rnase free cap 
and added 1 vol. Isopropanol, incubated 15 min at 4°C and centrifuged 13000 rpm at 4°C. 
Precipitate was dried under the vacuum for 2-3 minutes; 50 µl Rnase-free water was used for 
elution and incubated for 15 min at 60°C. 
The concentration and purity of RNA was determinate by measuring the absorbency (optical 
density) at 260 nm (A 260) and 280 nm (A280). An absorbency of 1 unit at 260 nm corresponds 
to 40 µg of RNA per ml (A260 = 1 = 40µg/ml) .The measurements were in water diluted  
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2:198, and purity was given trough the ratio between the absorbency values at 260 and 280 
nm. RNA was checked at 1% agarose gel for 10 min at 200V. 
DNAse treatment was done with 3 µg/µl of RNA, added 1µl  RQ1 DNAse (Promega) and 1 
µl RQ1 10 x buffer, and incubated for 30 min at 37°C, after was added 1µl RQ1 DNAse stop 
solution and incubated for 15 min at 65°C.Total RNA was stored at -80°C. Under these 
conditions no degradation of RNA was found. 
 
2.2.5.3 Generating full-length first-strand cDNA from an mRNA 
 
It was done with Ready To GoTM T-Primed First-Strand Kit. This kit has been designed to 
provide all the reagents necessary to generate full-length first strand cDNA from an mRNA 
template using an oligo (dT) Primer containing a NotI restriction site. It was used undegraded 
mRNA (gel check) for cDNA synthesis, about 5 µg of total RNA. The sample was brought to 
a volume of 33µl in an RNase-free micro centrifuge tube using DEPC-treated water, and 
heated to 65°C for 5 minutes just like Reaction Mix too. Both were transferred to a 37°C for 5 
min. RNA solution was transferred to the First strand Reaction Mix and was not mixed. It was 
incubated at 37°C for 5 min and mixed gently and centrifuged 1 min at 13000 rpm. After was 
incubated at 37°C for 60 minutes. The completed first-strand reaction was ready for PCR 
amplification. 
RTG-Mix components: 
• dATP, dCTP, dGTP, dTTP, FPLC pure 
• Murine Reverse Transcriptase 
• RNA guard (porcine) 
• RNase/DNase-free BSA 
• NotI-d (T)18 Primer  
(5‘-d[ ACTGGAAGAATTCGCGGCCGCAGGAAT18]-3‘) 
PCR check was with β-actin primers: 
BACTL l     5‘- GGCTGTATTCCCCTCCATCGTGG- 3‘ 
BACTL r     5‘- GCTCATTGTAGAAGGTGTGGTGCCAG- 3‘ 
95°C     1‘ 
95°C     35“ 
56°C     35“        40 x 
72°C     35“ 
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2.2.6 In situ hybridization 
 
In situ hybridisation (ISH) is the detection of a target DNA or RNA sequence in a tissue 
section using a labelled nucleic acid probe. It is still the only hybridisation technique which 
allows cellular and subcellular localisation of the target. The basic technique utilizes the fact 
that DNA and RNA will undergo hydrogen bonding to complimentary sequences of DNA or 
RNA. Specific DNA or RNA fragments may be readily identified within cells after 
hybridisation in-situ with appropriate DNA/RNA probes. During hybridisation at the cellular 
level, a labelled specific DNA or RNA probe locates onto complementary cellular target 
DNA/RNA. This probe is then detected with a suitably labelled antibody (Montgomery, 
2002). In situ hybridization experiments on whole mount embryos and paraffin sections were 
performed. 
 
2.2.6.1 Non radioactive In situ hybridisation on paraffin sections 
Fixatives and fixation  
Animals must be sacrificed with as little stress as possible and the tissue fixed quickly to 
avoid the contamination of the tissue with RNases on skin and laboratory instruments 
(Simmons et al., 1989). Tissue samples used in this experiment were collected from C3H 
mouse stem.  After removal from the animal, tissues were 'fixed' to preserve the living 
structure as closely as possible. The ideal fixative prevents tissue autodigestion (autolysis); 
inhibits bacterial or fungal growth (preserves); makes the tissue resistant to damage during 
subsequent processing, embedding and sectioning stages; is isotonic with the tissue and 
therefore does not alter tissue volume; does not distort any part of the tissue structure; does 
not dissolve tissue components and is not detrimental to the tissue component being studied. 
Fixatives for ISH should ideally retain mRNA within the tissue whilst preserving tissue 
morphology, but should not significantly raise background. At the same time they should 
allow probes to penetrate the tissue and hybridise with the maximum number of target 
molecules.  
Formaldehyde is the most common fixative in routine use. It is easy to prepare and stock 
solutions made up in phosphate buffered saline keep for months at room temperature. 
Commercial formaldehyde solutions contain ~40% w/v (~12M) formaldehyde in water and 10 
- 15% methanol. Formaldehyde is very water soluble and exists at low concentrations (4%) 
mainly as the monomer. At high concentrations (40%) it gradually polymerises and  
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precipitates as paraformaldehyde. Formaldehyde causes small changes in tissue volume 
during fixation, especially when dissolved in phosphate buffer, and the resulting morphology 
is very good for light microscopy. It penetrates tissue rapidly initially, but large tissue pieces 
fixed by immersion in formaldehyde solutions may not be fully fixed for days (Montgomery, 
2002).Paraformaldehyde is the most common fixative used for ISH. Tissue fixation is fast 
enough to prevent degradation of mRNA, but it is also easy to control the degree of fixation. 
Unlike formaldehyde, paraformaldehyde-containing fixative solutions have a short shelf life 
and need to be made up fresh each time. Paraformaldehyde is sold as a powder, which 
polymerises further with age. Old paraformaldehyde powder is difficult to dissolve and will 
not adequately retain mRNA within the sections during ISH. Glutaraldehyde is a very strong 
cross-linking di-aldehyde fixative. It is used for electron microscopy and for ISH with 
oligonucleotide probes (4% w/v glutaraldehyde and 20% w/v ethylene glycol in phosphate 
buffered saline).  
Paraffin-embedding 
Tissues are first dehydrated through graded alcohols and then 'cleared' with an antemedium, 
xylene. Paraffin wax and ethanol were immiscible, whereas antemedia were miscible with 
both compounds. After clearing, the tissues were infiltrated with paraffin wax. A range of 
waxes are available, whose melting temperatures are proportional to their chain length and in 
the range 42 – 60°C. Thin sections, ie ~ 2 mm and thicker, can be cut from tissues infiltrated 
wax with a melting point of 56 – 58°C.  
Sectioning 
Series of sections were cutted at 5 - 6 mm, picked up with forceps and floated first onto the 
surface of a cold water bath. Individual paraffin sections from the ribbon, were collected onto 
non-coated microscope slides and transferred to the 42°C water bath, and then recovered onto 
SuperFrost microscope slides. Sections onto the slides were drayed at 37°C.  
Probe Selection 
The first step of in situ hybridization is selection of a probe. There are several different probes 
that can be used, each with advantages and disadvantages. These probe types are double 
stranded DNA (dsDNA), single stranded DNA (ssDNA), single stranded complimentary RNA 
(sscRNA), and synthetic oligonucleotide. Which probes work for ISH has to be determined 
empirically (Montgomery, 2002). In this study RNA probes were used. One problem with  
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RNA probes are that they can have higher levels of non-specific binding to tissue 
components, which can lead to higher background and lower penetration of the probe into the 
tissue. 
Probe Generation  
There are a number of methods that can be used in order to generate a labelled probe for in 
situ hybridization. The generation of RNA probes utilizes in vitro transcription. In this 
method, the sequence is cloned into a vector containing phage transcription promoters that 
can initiate transcription in the presence of the corresponding RNA polymerase. If two 
different phage transcription promoters are placed on both sides of the polylinker cloning sites 
of the vector in opposite orientations, it is possible to selectively transcribe sense and anti-
sense RNA probes. Transcribing only one strand at a time prevents reannealing of 
complimentary strands during hybridization (Montgomery, 2002). By inclusion of either 
labeled or unlabeled nucleotides, it is possible to make labeled or unlabeled probes that can be 
used for different control procedures used in in situ hybridization. Single-stranded RNA - 
complementary RNA (cRNA) or riboprobes can be synthesised in vitro using one of the 
several commercially available phagemids. These contain promoters for the highly specific 
bacteriophage DNA-dependant RNA polymerases from the Salmonella bacteriophage SP6, 
and the E. coli. Bacteriophages T3 and T7. The three polymerases all have similar 
biochemical properties and consist of a single polypeptide chain. Each is highly specific for 
its own promoter and does not use other bacteriophage, plasmid, bacterial or eukaryotic 
promoters at a significant rate. For ISH, subclone an insert in the range 500 - 1000 bp in 
length. This is large enough to be sensitive, but small enough to penetrate tissue without prior 
hydrolysis. 
Probe Labels 
For In situ hybridisation RNA probes were labelled with Dioxigenin-rUTP (Boehringer 
Mannheim) were synthesized from linearized cDNA templates according to the 
manufacturer’s instructions. Hic2 probes were linearized with BamHI and XhoI , and 
synthesized with T7 and Sp6 RNA polymerase. Control En1 (engrailed) probe was obtained 
from M. Panyhuesen, linearized with BamHI and HindIII, and synthesised with T7 and T3 
RNA polymerase. 
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Prehybridization of slides  
Slides were dewaxed in xylol 1 X 5 min and 2 X 10 min. Then dehydrated trough EtOH 
series: 95%, 90%, 80%, 70%, 50%, and 30% each for 2 minutes. Washed in PBS 2 X 5 min; 
4%PFA in PBS for 30 min at room temperature; PBS 2 X 5 min. Treated with Proteinase K 
(2µg/ml) in Proteinase K buffer approx. 3 minutes. After that washed 2 x 5 min with PBS; 
4%PFA for 30 min; PBS 2 X 5 min; 2XSSC 2 X 2 min; Tris/Glycine buffer for 30 min or 
longer. All steps prior to and during hybridization were conducted under RNase-free 
conditions. Sections were deparaffinized with xylene (5 min X 3 times), and rehydrated 
through descending ethanol concentrations [100% (5 min X 3 times), 90%, 80%, 70% and 
50% (5 min each) and PBS (10 min). The sections were treated with Proteinase K (2 µg/ml in 
PBS), pH 7.4 at room temperature (RT, about 20°C) for 15 min. The slides were then 
immersed in 0.2% (w/v) Glycine in PBS (10 min) and PBS (3 min X 2 times). The sections 
were acetylated for 20 min with 0.25% (v/v) acetic anhydride in 0.1 M triethanolamine 
(TEA), pH 8.0 and the slides were washed twice in 4 X SSC (10 min each). The 1 X SSC 
solutions consisted of 0.15 M sodium chloride and 0.015 M trisodium citrate. Following 
incubation with 50% (v/v) deioned formamide/2 X SSC solution at 42°C for 30 min, the 
sections were incubated with hybridization solution which contained approximately 0.5 µg/ml 
DIG-labelled probes in hybridization buffer (50% deioned formamide, 10% (w/v) dextran 
sulphate, 1 X Denhardt's solution and 200 µg/ml tRNA in 0.6 M NaCl; 10 mM Tris-HCl, 
pH7.4; 1 mM EDTA, pH8.0). On each slide 100 µl hybridization solution were applied. Slides 
were then incubated in a humidified chamber at 42°C for 16 h.  
Hybridization 
Hybridization is performed by placing a small amount of solution containing the hybridization 
probe on a cover slip, which is then placed on the slide containing tissue sections to incubate 
overnight. It is important to work out all bubbles from under the cover slip. Hybridisation mix 
contained next components: 50% Formamide, 5XSSC, heparin (2 mg/ml), 0.1% Tween20, 
100 µg/ml denatured tRNA and denatured probe (3 min at 80°C) diluted 1:50 or 1:100, 5% 
dextransulphate. Slides were taken out of the Tris/Glycine buffer one after other, fluid was 
removed with paper. The labelled probe is resuspended in hybridisation buffer and then 
hybridised under a coverslips, with the dehydrated tissue sections it was needed 120 µl 
hybridisation mix per slide, and slides were covered with coverslips and placed horizontally 
in plastic boxes (Haereus). Boxes were putted in tissue soaked with 5 X SSC and in foil (wet 
chamber effect) and placed at the oven bottom and incubated at 65°C over night. 
39 
Removal of the unbound probe 
The next day, washes are serially applied to the slides to remove the probe that is not bound to 
target DNA/RNA. This removed the free probe, dextran and blocking agents. The coverclips 
were floated off in 5 X SSC at RT, washed in 0.5 x SSC/20% FA 4 X 30 min at 65°C for 1 hr 
with changed of washing solutions and cooled down to 37°C. Washed in NTE buffer for 15 
min at 37°C; NTE + 10 µg/ml RNAse A, for 30 min at 37°C; NTE for 15 min at 37°C; in 0.5 
X SSc/20%FA for 2 hours at 65°C; in 2 X SSC 2 X 15 min at RT. Stored in 1% blocking 
solution in MABT until the antibody was added. After hybridisation, probes were recognized 
by an anti-digoxigenin antibody conjugated with alkaline Phosphatase. Dig antibody was 
diluted 1:5000 in 1 % blocking solution and shacked at 4°C for 1-3 hours. Per slide was added 
120 µl of 1% blocking solution + antibodies. Slides were covered with cover slips and placed 
horizontally in plastic boxes. Boxes were putted in tissue soaked with 5 X SSC and in foil 
(wet chamber effect) and putted at 4°C over night. 
 
Removal of unbound antibody 
The coverslips are removed in TBST and the sections then washed in TBST for 1 hr and in 
NTMT 2-3 X for 10 min at room temperature. This removed unbound antibodies and blocking 
agents. 
 
Detection of the staining 
Staining was done with BM purple AP substrate. That is a chromogenic substrate for alkaline 
Phosphatase (AP) designed for precipitating enzyme immunoassay. It develops a permanent, 
dark purple band or spot at the AP binding site (Montgomery, 2002). 
Before use BM purple AP was centrifuged at 2500 rpm (Rotor 12154-H, Sigma 3K18) for 7 
minutes and added 2 mM Levamisol and 0.1% Tween 20. On each slide 120 µl staining 
solution were applied. Then the slides were incubated in a humidified chamber overnight at 
4°C. 
After finishing the staining slides were washed 2 x 15 min in NTMT and refixed in 
4%PFA/PBS for 5 min. Finally, slides were 2-3 times with Millipore-water washed. Kaiser’s 
Glycerol gelatine was warmed up in a water bath at 50-55°C until it was liquid. Fluid from the 
slides was removed. On each slide 500 µl Kaiser’s Glycerol gelatine were applied and 
covered with a cover slip. 
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2.2.6.2 Whole mount In situ hybridisation 
 
ISHs of whole mount embryos (WISHs) were performed according to Spörle and Schughart. 
The embryos were prepared in PBS, fixed in 4%PFA/PBS over night at 4°C, washed twice 30 
minutes on ice with PBS, dehydrated on ice through 25%, 50%, 75% and 2 x 100 
MetOH/PBS/DEPC, 10 minutes each and stored at –20°C. 
 
Pre-hybridisation  
Embryos were rehydrated on ice through 75%, 50%, 35% MetOH/PBS, and 10 minutes each. 
Washed on ice 2 x 10 minutes with PBT, bleached with 6% H2O2 in PBT for 30 minutes, 
after that washed again 3 x 10 minutes with PBT. Treated with Proteinase K (1µg/ml) in 
Proteinase K buffer approx. 5 minutes. After that washed 2 x 5 min with PBT/glycine, 2 x 5 
min with PBT, 3 x 10 min with RIPA buffer, 3 x 5 min with PBT. Fixed exactly 20 min with 
4%PFA/0, 2%glutaraldehyde in PBT on ice, washed 3 x 5 min with PBT and sorted in Cryo 
vials because of very small hybe volume. Washed at RT in hybe-buffer/PBT (1:1) 10min, 
hybe-buffer 10 min and incubated with hybe-buffer at 65°C for 3 hrs. 
 
Hybridization  
Probes were denaturatied at 80°C for 3 min, hybed embryos in prewarmed 65°C hybe-buffer 
with tRNA (100µg/ml, 1:50-1:100 diluted DIG labelled probe (0,1-1µg/ml), putted over night 
in rotating oven at 65°C. 
 
Removing of the unbounded probe 
Started with wash 2 x 30 min at 65°C with hybe buffer, 5 min with 1:1 hybe buffer/RNAse 
solution, incubated 2 X 30 min at 37°C with RNAse solution contained 100 µl RNAse A. 
After that incubated in 1:1 RNAse solution/SSC/FA/Tween20 for 5 min at 37°C. Embryos 
were heated in SSC/FA/Tween20 from room temperature to 65°C and washed 4-5 hours at 
same temperature with SSC/FA/Tween20.Then were cooled down, washed 10 min at RT in 
1:1 SSC/FA/tween20/TBST; 3 X 10 min at RT with 1 X TBST; 2 X 10 min at RT in MABT; 
incubated for 1 hr at RT in 10% blocking solution/MABT. At the same time were preadsorbed 
Dig antibodies at 4°C for 1 hr in 1% blocking solution/MABT, diluted 1:5000. Embryos were 
incubated I antibody solution at 4°C over night, while shacked.  
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Remove unbound antibody 
Embryos were washed 3 X 5 min at RT with TBST and whole day with TBST at RT. Were 
left in TBST on shaker 3-4 days; TBST was exchanged every two days. 
Staining 
Staining started with wash step: 3 X 20 min with alkaline Phosphatase buffer pH 9.5, stained 
were in staining solution with 0.1% Tween20 and 2 mM Levamisol ; Solution was centrifuged 
before use 7 min at 2500 rpm and changed before was turned from yellow to purple. Embryos 
were developed at 4°C in the dark. Staining was followed with dissecting microscope; 
embryos were washed 3 X 20 min in alkaline phosphates buffer, fixed in 4%PFA/PBS over 
night and stored in same solution for several months. 
2.2.6.3 Staging of Embryos 
Because of differences in the time of implantation and in individual rates of development, 
embryos develop at variable rates after fertilization. In fact, at any particular day of gestation 
the embryos of each litter may exhibit considerable variability in their apparent morphological 
state of development. The Theiler (Theiler, K., 1972 and Butler and Juurlink, 1987) staging 
systems can be used to reduce this developmental variation. These staging systems assign 
embryos to one of several specifically defined stages of development. For the gestational ages 
referred to in Table 1 below, the morning on which the vaginal plug is found is counted as day 
one (E1) of gestation. The characteristic external features that can be used to assign an 
embryo to a specific Theiler or Carnegie stage of development are compiled from Theiler 
(1972), from Butler and Juurlink (1987) and from personal observations. Note that up to 
Theiler stage 19 each stage covers a half day of gestation, but the subsequent stages each 
cover about one day of gestation. The Carnegie system can only be used to stage embryos 
during the embryonic period of development (up to ~E17.5 for rats and E16 for mice), 
whereas the Theiler stages cover the whole period of intrauterine development.            
                                                             
                                   Gestational Age    
Theiler Stage    Carnegie Stage     Mouse     Rat 
      14                           11             E10      E11.5 
      15                           12             E10.5   E12 
      16                           13             E11      E12.5 
      17                           14             E11.5   E13 
      18                           15             E12      E13.5 
      19                           16             E12.5   E14 
      20                           17             E13      E14.5 
                                     18             E13.5   E15 
      21                           19             E14      E15.5 
                                     20             E14.5   E16 
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      22                           21             E15      E16.5 
                                     22             E15.5   E17 
      23                           23             E16      E17.5 
      24                         N/A            E17      E18.5 
      25                         N/A            E18      E19.5 
 
Mice were obtained from the GSF animal facilities. 102 x C3H mice were used for the supply 
of all tissues and the preparation of embryos. 
 
 
2.2.7 Northern Blot 
RNA transfer to the membrane 
Electrophoresis 
After RNeasy Mini Kit total tissues RNA preparation the same was tested on the special 
Agarose-Formaldehyde gel. Gel box was cleaned with NaOH and SDS overnight, and rinsed 
with DEPC-water. For 1.2% gel in 150 ml was used 1.8 g agarose, 15 ml 10X MOPS buffer, 
130.5 ml DEPC-water and 7.6 ml Formaldehyde.  
 
Sample preparation 
 Every slot contained about 20 µg of total RNA from liver, brain, kidney, testes, lung, and 
whole mouse embryos RNA stage 12.5 and 13.5. RNA brought to the equal volume with 
DEPC-water, added the same volume loading buffer and 0.5 µl EtBr (0.5 µg/µl), heated for 5 
min at 90 °C, cooled on ice. 
 
Gel run 
17 hours at 25V in Loading Buffer (1X MOPS/EDTA) the gel runned 
0.24-9.5 kb RNA Ladder was used for size control.  
 
Northern transfer of RNA 
After 17 hours gel was soaked 3 times 5 min in distilled water (to remove Formaldehyde) and 
photographed with ruler beside it in 0.05 M NaOH/ 1X SSC washed, and for 20 minutes in 10 
X SSC. 
Capillary blot with 10 x SSC transfer buffer was seated up: 
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 2 wet Whatman - gel – membrane (Hybond TM-N+ Membrane (Amersham Pharmacia 
biotech), optimised for nucleic acid transfer and was soaked in water for a few seconds. - 2  
wet Whatman - 2 dry Whatman - paper towel - glasplate - weight.   It was 16-24 h with 
transferred with changes of the paper towel. Lanes were marked, membrane removed, washed 
briefly in 2 x SSC. Membrane was placed on wet Whatman paper and UV-crosslink damp 
(auto crosslink setting, 254 nm, Stratagene, Stratalinker) and baked at 80 °C for 1-2 h. 
 
Hybridization 
For 1-4 h membrane was prehybrizated at 42 °C with 5-10 ml prehybridization buffer. The 
0.5 kb EcoRI-NotI insert of the CloneID 337300 was labelled with [[α]-32P] dCTP 
(Amersham). Radioactive labeled probe heated for 3 min at 95 °C, cooled on ice. 
Prehybridization buffer was discarded; hybridization buffer and probe added and incubated 
ON at 42 °C. Washed 1 x 15 min with 2 x SSC at RT, 2 x SSC, 0.1 % SDS at 65 °C, and with 
0.1 x SSC, 0.1 x SDS at 65 °C (optional). Wet membrane was exposed under saran wrap (-80 
°C).    
 
Stripping and re-hybridization 
 For 30 min to 3 h membrane was washed in strip solution at 75 - 85 °C until no radioactivity 
can be detected on the membrane. Air dried and stored at RT for re-hybridization (up to 10 
times) follows the hybridization protocol. 
 
 
2.2.8 Promoter Analysis 
 
The construct of the Hic2 promoter analysis included: 
1. Promoter PCR analysis 
2. Promoter in the pCR.IITOPO Vector 
3. Promoter in pPLLucII Vector 
4. Transfection of the promoter deletions and reporter gene  assay 
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2.2.8.1. PCR amplification of promoter sequences  
 
About 1.2 kb of promoter sequence was divided in 5 deletions. First step was PCR reaction.  
Cycle    Reaction Time   Temperature  Repeats 
 1     Denaturation            1 min                   95°C                     1 X 
 
        Denaturation           35 sec                 95°C 
2      Annealing               35 sec                 46°C                40 X   
        Extension                    35 sec                 72°C 
3  Extension                    10 min                72°C                      1 X 
 
 Products were excised from the gel and extracted with NucleoSpin® Extract 2 in 1. For each 
100 mg agarose gel it was added 300 µl NT1 buffer, was incubated at 50°C for 10 minutes 
and centrifuged 1 min at 13000 rpm (Rotor 12154-H, Sigma 3K18). Than it was added 500 µl 
buffer NT2 and again centrifuged for 1 min at the same speed like by step before. After it was 
added 600 µl buffer NT3 and centrifuged for 1 min at full speed; added 200 µl buffer NT3 
and centrifuged for 2 min at full speed. Last step was elution with 30 µl elution buffer NE. 
The PCR products were cloned Forward primers contain an XhoI site for cloning, whereas the 
reverse PCR primer has a BamHI restriction site.                                 
 
2.2.8.2 Promoter in the pCR.II-TOPO vector 
Forward primers contain an XhoI site for cloning, whereas the reverse PCR primer has a 
BamHI restriction site. 
It was taken 4µl of the extracted DNA and 1µl of salt solution and mixed and incubated at 
room temperature for 5 min. Transformed with DH5α cells. Ligated and incubated at ice for 
30 min, applied heat shock at 42°C for 45 seconds and putted back on the ice. Added 250 µl 
of LB medium and incubated at 37°C on a shaker for 1 hour. Incubated mix was putted on the 
LB-IPTG-X-GAL plates, and incubated overnight at 37C°.Next day were picked white 
colonies and incubated in shaker at 37°C for 1 hour. 
The positive samples from the promoter pools were cultured overnight at 37°C with LB 
medium + Ampicilin. Next day performed plasmid extraction only from the cultures that has 
become turbid followed the protocol of the kit.  
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2.2.8.3 Promoter in the pPLLucII Vector 
The pPLLucII Vector empty (Y.Kamachi) was prepared with SalI/HindIII restriction sides. 
The PCR products were cloned into the cloning site of the pPLLucII reporter vector using 
SalI/BamHI and HindIII restriction enzymes. For fragments in 5’-3’ orientation was used 1 µg 
of Vector (2 µl) was used, 4 µl Y+ buffer, 0.5 µl SalI, 0.5 µl HindIII and 13 µl water; 
incubated for 60 minutes at 37°C, heat inactivated for 15 min at 65°C and dephosphoryled 
with 3 µl Dephosphorilatyon buffer, 2 µl water and 5 µl Alkaline Shrimp-Phosphatase. 
Incubated for 10 min at 37°C, heat inactivated for 15 at 65°C. From the pCRII-TOPO Vector 
insert was released with HindIII/XhoI restriction enzymes. PCR products were excised from 
the gel and extracted with NucleoSpin® Extract 2 in 1 and eluted in 35 µl water, added 2 µl 
pPLLucII Vector (empty), 4 µl Rapid Ligation Buffer, and 1 µl T4 Ligase; incubated at room 
temperature for 60 minutes and stored at 4°C over night and transformed with DH5α cells,  
Placed on the LB-IPTG-X-GAL plates, and incubated overnight at 37C°. Next day were 
picked white colonies and incubated in shaker at 37°C for 1 hour. The positive samples from 
the promoter pools were cultured overnight at 37°C with LB medium + Ampicilin. Plasmid 
extraction was performed only from the cultures that have become turbid. 
 
2.2.8.4 Transfection and reporter gene assay 
For Luciferase (Luc) reporter assay, HEK-293 fibroblast cells were cultivated in 96-well 
plates for 24 h and transfected by PolyFect Transfection Reagent (Qiagen) using 0.7 µg 
plasmid-DNA. PolyFect Reagent is a solution of specifically designed activated-dendrimers; 
consist of dendrimer molecules of a defined spherical architecture with branches radiating 
from a central core. The branches terminate at charged amino groups, which can interact with 
negatively charged phosphate groups of nucleic acids. PolyFect Reagent assembles DNA into 
compact structures. This reagent is provided as a ready-to-use solution. The DNA mix in 
transfection reaction is compounded by 0.5 µg reporter vector, containing a sequence 5’ of 
Hic2 fused to the Luc reporter gene 0.1 µg effector (parental plasmid pcDNA3.1 as negative 
control) and 0.1 µg pRL-SV40 for transfection control. Cells were harvested 48 h after 
transfection and cellular extracts were assayed with the Dual-Luciferase Reporter Assay 
System (Promega). 
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Vector   End conc. 
pPLLucII  0.63 µg 
pcDNA3.1  0.18 µg 
pRLSV40  0.09 µg 
 
The cells were divided to the 96-well Plate, dilution was 1:3. It was taken 2 ml from the cell 
suspension, added 8 ml DMEM Medium to the end volume 100 µl pro well. The transfection 
pool was done with pPLLucII Construct 3 x 0.21µg in the DNA pool (Promoter construct 1-
5), pcDNA3.1 3 x 0.06 µg in DNA pool, pRLSV40 3 x 0.03 µg in DNA and mixed. PolyFect 
3 x 1 µl and DMEM (without all) added to 30 µl in the PolyFect pool and mixed. PolyFect -
pool was added to DNA-pool and incubated for 10 minutes at room temperature. To the cells 
in the wells were added 50 µl from the fresh DMEM Medium (with all), after was added fresh 
DMEM Medium (with all) and already 80 µl pro well, incubated 40-48 hours at 37°C under 
5% CO2.  
 
Vector  0           1   2    3      4         5  End conc. 
pPLLucII 23 17.5   4   6.3      8     10.2  0.63 µg 
pcDNA3.1 4.6 4.6  4.6   4.6      4.6       4.6  0.18 µg 
pRLSV40 3.6 3.6  3.6   3.6      3.6       3.6  0.09 µg 
DMEM 13.8 19.3 32.8 30.5     28.8      26.6 to 45 µl 
 
2.2.8.5 Measurements 
For this part of experiment Dual-Luciferase ®   Reporter Assay was used, which contains an 
optimised Lysis reagent for preparing cell lysate and all of the reagents necessary for the 
sequential assay of firefly and Renilla Luciferase, and Plate-reading Luminometer. The term 
“dual reporter” refers to the simultaneous expression and measurement of two invidual 
reporter enzymes within a single system. 
Passive Lysis Buffer is supplied as a 5X concentrate. Reagent was prepared like 1X 
concentration by adding 1 volume of 5X PLB to 4 volumes of distilled water. The 5X PLB 
was stored at -20°C. From the cultured cells was removed the growth medium and applied 20 
µl of 1X PBL. The culture plate was placed on an orbital shaker and shacked for 10 minutes  
at room temperature. After that culture plate was stored at -80C° for 20 minutes, and for 20 
minutes at room temperature. Luciferase Assay reagent II (LAR II) was prepared by 
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resuspending the provided lyophilized Luciferase Assay Substrate in 10 ml of supplied 
Luciferase Assay Buffer II, mixed and stored at -20C°. Stop & Glo® Substrate was supplied in 
a 50X concentration. It was added 1 volume of 50X Stop & Glo® Substrate to 50 volumes of 
Stop & Glo® Buffer. 
 
Luminometer (Ultrospec III) contained injector and measurement part, was connected with 
computer. Measurement program was called “Simplicity”. The first step was injector lines 
cleaning. Position 1 (Firefly) to Mpl (Micro plate), 500µl 10X, position 2 (Renilla) to Mpl 
(Micro plate), 500µl 10X, together were 3 wash steps, 1X with H2O, 1X with 70% EtOH, 1X 
H2O. Next step was air soak. The injector lines were putted outside of the solutions, and 
soaked air (empty). Pos. 1 (Firefly) to Mpl (Micro plate) 300 µl 3X, Pos. 2 (Renilla) to Mpl 
(Micro plate) 300 µl 3X, all time injector lines were on the air. In the next step were soaked 
LAR II and Stop & Glo. Wash solution were changed with measurement solutions. Pos. 1 
(firefly-LAR II) to MPL (Micro plate) 200 µl 3X, Pos. 2 (Renilla- Stop & Glo) to Mpl (Micro  
plate) 200 µl 3X. On the wash plate was made control was it really sucked. For measurement 
A1 corner from the micro plate was putted in the right up corner. 
 
Protocols: RD Raw Data, Dual: Pos. 1 Firefly, Pos. 2 Renilla, And FK Fast Kinetics 
Injector was cleaned again. Measurement solutions were sucked back to the bottle. Pos. 1 
(Firefly) to bottle 300 µl 3X, Pos. 2 (Renilla) to bottle 300 µl 3X. The last step was done like 
a first one, Position 1 (Firefly) to Mpl (Micro plate), 500µl 10X, position 2 (Renilla) to Mpl 
(Micro plate), 500µl 10X, together were 3 wash steps, 1X with H2O, 1X with 70% EtOH, 1X 
H2O. The injector lines were putted in the water and Luminometer was switched off. 
 
 Calculations were done with Microsoft Excel program in three steps: 
1. Middle value from the zero value 
2. Relative Luciferase activity 
3. Normalisation  
 
For relative Luciferase activity was used next formula: 
RLA= (measurement n* - middle value) [Firefly] / (measurement n*-middle value) [Renilla] 
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Normalisation: 
N value = Relative Luciferase Activity n*/ middle value** (relative Luciferase activity”0”) 
* were own measured results (1-3) 
** (relative Luciferase activity”0”) 
The calculations for graphics were done with Sigmaplot program which made a graphics 
already.   
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3. Results 
 
    3.1 Isolation of the mouse Hic2 gene 
Searching the cDNA-Bank from Clontech with a 0.9 kb EcoRI/NdeI Hic1-fragment, a new 
clone λC5-1-1 was found. The clone C5-1-1 had one 2kb long insert. The DNA sequences 
from C5-1-1 and Hic1 were identical but just in the 3’part of the sequence which coded zinc 
finger domain and in the 3’UTR of the Hic1 and γFBP proteins. Screening of the EST 
database (dbEST) with the C5-1-1 sequence detected one EST clone 2.9kb (AA118503, 
I.M.A.G.E. clone ID 555891). This clone is generated from mouse paws E13.5 cDNA bank 
and began with zinc finger domain followed a 3’ untranslated region (Fig.3.1A). The new 
isolated cDNA was named Hic2, and presented a paraloge of Hic1. The sequence C5-1-1 is in 
the Gene Bank under number AF117382 (Grimm C., 1999, Dissertation). 
 
Does Hic2 contain important domains such as GDLSK and BTB/POZ, like its paralog Hic1 ? 
 
The open reading frame in the 5’ part of the C5-1-1 sequence was not evident it was not 
possible to get 5’ of the sequence and promoter region. In the GSS-Database were identified 
E16R and F08, two mouse genomic clones, ordered by Utah Genome Centre. 
The F08 clone defined 3’sequences, began with a zinc finger domain, and coded the stop 
codon and poly-A tail.  
The E16R clone defined 5’sequences, began with a part of 3’UTR, followed by the zinc finger 
domain and encoded two domains GLDLSK/K and POZ/BTB. The long E16R sequence was 
compared with Celera data base and a big genomic clone about 500 000 bp was identified 
(Fig.3.1B). This clone contained the complete Hic2 gene sequence. Parallel with sequencing it 
was possible to use Ensemble Mouse data base which already showed position of the Hic2 
transcript in the Mouse genome. 
 
 
 
50 
 
A 
Hic1 probe                      0.9 kb  
                                                                                               TAG 
 
C5-1-1                             2 kb 
 
                                                                                                TAG 
EST (AF117382)           2.9 kb AAA 
 
 
 
B                                                                     TAG 
F08 (mouse genomic)                                                                                                           AAA 
                                                                                                TAG 
                                                                                                         E16R (mouse genomic)  
                                                                                                TAG 
                                                                                                                                             AAA 
CELERA genomic 500 kb 
 
 
Figure 3.1. Hic2 cDNA clones. A) Hic1 probe isolated C5-1-1 Hic2 clone and in the database 
identified Hic2-EST clone (Grimm C.) B) New Hic1 probe positive clones. The UGC1M0225E16R 
and UUGCIM0327F08 clones helped with identity the Hic2 genomic structure and were used to 
localize Hic2 to chromosome 16.  
 
 
 
        Zinc fingers 
        GLDLSK/K domain 
        BTB/POZ domain 
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3.2. Genomic organisation of the Hic2 locus      
                                           
Database searches with genomic Hic2 sequence revealed similarities with human HIC2 gene, 
some members of KIAA1020 and DKFZp434F0616 protein, as well as human HIC-3 gene. 
The search did not show high identity with any of the mouse gene sequence (Fig.3.2). 
 
 
 
 
 
Figure3.2 Nucleic acid sequence homologies between Hic2 and some genes showed the highest 
percent identity with human mRNA for HRG22 (HIC2) protein. 1) Homo sapiens HIC1-related gene 
on Chromosome 22, 2) Homo sapiens mRNA for HRG22 (HIC2) protein, 3) Homo sapiens mRNA 
DKFZp434F0616, 4) Homo sapiens mRNA for KIAA1020 protein and 5) Homo sapiens HIC-3 
mRNA 
 
In silico analysis demonstrated that the complete HIC2 (HRG22) coding sequence and the 
large 3’ untranslated sequence were collinear with a unique genomic region. The Hic1 coding 
sequence and the large 3’ untranslated sequence were not completely collinear with the Hic2 
coding sequence (Fig.3.3). More identities in genomic locus showed Hic2 with its human 
orthologues HIC2. 
 
Using several gene prediction programs (Genescan, Webgene), the highest score for a splice 
acceptor site in the 5’ Hic2 genomic sequence highlighted a sequence located 40 bp upstream 
of the putative BTB/POZ initiation codon ( Fig.3.3 and  3.4).  
The 5’ boundary of the Hic2 exon that was named exon 2 (Fig. 3.3), was fully validated by 
the identification in the database of a mouse mammary tumor tissue EST BI654062 and the 
human kidney EST BE501479.  
85%
86%
87%
88%
89%
90%
91%
1 2 3 4 5
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Analysis of the Hic2 genomic sequence upstream of exon 1, WebGene program predicted a 
putative TATA box (position 5807), pattern (Fig. 3.4). 
In the 5’ end of the Hic2 exon 2 the WebGene program predicted 2 CpG islands at the 
positions 4099 to 4342, and 5285 to 5580. This fact could play a role in promoter activity and 
hypermethylisation. The first CpG island (4099-4342) is located in the 5’ of exon 2, and the 
second one (5285-5580) in the 3’ part of Hic2 intron (Fig. 3.3).  
 
 
 
 
 
 
 
 
                                                                     HS EST 
 
 
                                                                     MM EST 
 
 
 
 
                                                                      RT-PCR 
 
 
 
 
 
Figure 3.3 Schematic genomic structure of the Hic2 locus and comparison with the related HIC2 and 
Hic1 locus. The structure of the Hic2 locus has been deduced from the partial cDNA clone C5-1-1, 
mouse ESTs clone BB659883, generated from lung E13; BQ965108, generated from undifferentiated 
limb; BI654062 generated from mammary tumor tissue, 5 month old mouse. Human EST clone 
BE501479 generated from kidney, and the nucleotide sequence of a RT-PCR product. Comparison of 
the genomic Hic2 and the cDNA sequences revealed two exons, separated by a 2kb intron. 
 
ATG TAG 
1a ZF
TATA 
ATG 
Hic1 MOUSE 
1b 
1,4 Kbp 
ATG TATA TAG ATG 
1 
2,0 Kbp 
HIC2 HUMAN 
ZF 
ATG TAG 
1 2 ZF
TATA 
ATG 
Hic2 MOUSE 
CpG CpG 
2,2 Kbp 
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The exon-intron boundaries are in good agreement with the splice site consensus sequence. In 
comparison with the human HIC2, the beginning of the exon 2 sequence are almost identical. 
Position 2584 in mouse sequence is one C and in human the same position is G; the codon in 
the human sequence is GCG for alanin, while in the mouse  the triplet is CCG for prolin. In 
the mouse sequence the position 2625 is A, and in the human sequence C. The codon triplets 
are CCC and a CCG, respectively, both are for prolin. The WebGene program predicted 
potential splice signal, for donor site position 2588 CAG…GTGGTG and for acceptor site 
position 397 GCTTTGCAG…TATA (Fig. 3.4). 
 
 
Exon 2 
 
                                 W     C     A     W      A      G      R      G      D      M      G      P      D      M      E 
HIC2…tgcccacag  GTG-GTGCGCGTGGGCAGGGCGCGGGGACATGGGGCCCGACATGGAG 
Hic2…tgcccacag   GTG-GTGCCCGTGGGCAGGGCACAGGACATGGGGCCAGACATGGAG 
 
 
Figure 3.4 5’ boundary of the human HIC2 and mouse Hic2 exons 2. The splice donor sites are 
underlined. The noncoding and intronic sequences are shown as lowercase letters, the coding 
sequences are indicated as capital letters.  
 
 
To address the functionality of TATA box as a putative promoter, RT-PCR was done using 
normal mouse brain (newborn) cDNA, since this organ yielded the highest level of Hic2 
expression. One nested sense primer (E1-L) located just downstream of the putative TATA 
box, and one nested antisense primer (EX2-M-R1) in the Hic2 exon 2 yielded a fragment of 
the expected size (Fig. 3.5A).  
 
Northern analysis of total RNA from kidney of new born mice revealed a single transcript 
about 1.9 kb (Fig. 3.5 B) suggesting that the complete transcribed region of Hic2 including 
the entire coding region was identified. 
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A                                                                                 B                    Kidney 
 
    
Fig. 3.5  
A) RT-PCR with nested primers demonstrated that this band corresponded to the correct splicing of 
exon 1 sequences to exon 2. The primers yielded a fragment of the expected size (450bp). 1 and 2 for 
E 12.5 cDNA, 4 and 5 for brain (new borne mouse) cDNA  
B) Northern analysis showed a single transcript about 1.9 kb, the total RNA (tRNA) was isolated from 
the mouse  kidney (new borne).  
 
 
 
The Hic2 transcript is located on mouse chromosome 16 position 16000001-17000000 
complement 727777 to 729582, join the complement 727777 to 729582. A transcript which is 
similar to Homo sapiens Hypothetical protein [ DKFZp434H177.1] is  located 5’ to the Hic2 
on the chromosome 16 16000001-17000000, complement 707799 to713403. There genes are 
located in the 3’flanking region from Hic2: an SDFZ like protein at position 16.16000001-
17000000 complement 749673 to 751535, an MIR stromal cell-derived f2-like at  
complement 600878 to 602681, and an NAS hypothetical protein at complement 609377 to 
614455. 
 
The deduced Hic2 protein consists of 601 amino acids including a POZ domain and five 
C2H2 zinc fingers at the C terminus (Fig. 3.9). Following the POZ domain, Hic2 contains a 
cluster of basic amino acids, RRKLKRAKK (Fig. 3.6). Coding exon (2) containing a long 
ORF yielding 617 amino acids protein (Fig. 3.6). 
 
 
 
 
 
 
MVIII 1116 bp 
 501 bp 
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Hic2 genomic sequence 
 
 
        1 CGAATTGGGC CCTCTAGATG CATGCTCGAG CGGCCGCCAG TGTGATGGAT ATCTGCAGAA 
       61 TTCGCCCTTG CAGCTAGGTG GCATTATGTA GCCTTTAAAG CACATTGTAA ATGTCCCTTG 
      121 CCTTTAATCC CAGCACTCCC AGAGGCAGGT GGGTATCTGT AAGTTCGAGG CCAGCCTGCT 
      181 CTATGTAAGA GGGTTCCTGT CGAAAGGAAA GGAAAGGAAA GGAAAGGAAA GGAAAGGAAA 
                                        GKLF                  EVI1 
      241 GGAAAGGAAA GGAAAGGAAA GGAAAGGAAA AGAAAGGAAA AGAAAGGAAA GGAAAGGAAA 
      301 GGATACAGGG AGGGGGCATC TTAGGAGGCT AAAGGCAAGA CACAGCTGGC TGTCAGGAGG 
                  SP1,WT1                                AP4 
      361 CTAGGGCAAG GCTGGCCATA TTTACATAAC AAAAGGTCAA AACCAGGAGC CACTTGTGGA 
                     p53 
      421 AGGGCTATTT ATAAGAGCCA ATCTGCCTCT ACTGCCTCTT TCCCCTTCTT TCCTTGGCAA 
                           CCAT box 
      481 CAGGGCTCTT CTGTCTACAG GCTCAACTCA GCACAACAAC CAACAGCAAC CGGGTGAGGG 
      541 GTGCTCTCTG CCGCCATCAC TCTGTGTTCT ACAAGAGGAG GGATCTTGAG GTTCTGGATC 
      601 CCTGTACTCC ATACAGAACG GCAGCCTGGT CTCCCCTGGA ACAAGCAGGG GTAGGAGGAG 
      661 CCTGCAGCAG GCAAGAATCC ATCTCTGACA GCCCTTCCCC CACACCATCC CTAGGGCCAG 
                                              WT1,ZBP-89 
      721 AGGACAGGTC CTTCAGGAAT GTGACCAGAC CTGGAAGGGC GAATTCCAGC ACATTTACAA 
      781 TGTGCTTTAA AGGCTACATA ATGCCACCTA GCTGCTCATA TCTAAAACAA GGTCTCTCTT 
                 TATA 
      841 TTTTTGGTGT GTGTGTATGT GTGTCTCATT TTTTTTCCTC TTGCTTTGTT GCCTCAGGTG 
      901 TTTGTGAACC TCTTTGGGAG TAGAGACCCC CCCACCCCTT GTTCCTCTCT TCTCCTCCGT 
      961 CCCTCACTGA TGCCTGCTTT TTTTTCTCCA GGTAACCAGG CTTTGATGCA CCCTCAGGAA 
     1021 GTCTGTGCAC TCGAGGAGGC CACCCCCCGC CGGCTGCTGC TCACATGGTT TCTGGGCCCC 
     1081 TGGCACTCCG GTAGGCCTGG GAGAGGAAGA ATCACCACTG GTTTCCAGTC CTTGGGGCTT 
     1141 CCTGGGTCTC TCATACAGCT TTGCAGTATA cattctgtcc tggccctcag aattcaggtt 
     1201 gctatatgtg cacagtgcag gcaggcagca tgtggggtgt ctaggacttg tggcccaggc 
     1261 cttggccaca tatagctttt cttttatttc tcttggtagg cctgaggtac cagctattat 
     1321 tgctggcaga gctggcactg ccattgcctt ggggctgata tatagggcct gtgtggaaat 
     1381 cataccttag gctctttgtt tctacttagc atgtggagaa gccttggttt tcctcatctc 
     1441 cagccactca gtatcccact gatgtgcttc agctgttgtg ggcaaggggc aggcaggcag 
     1501 agccctctgg caggtgctgg taggaccgag tgttagcatt cctgtaacgt ttctgttgac 
     1561 tcacagtgtg ctgggttatt agcttccttc tctgaacagg gcagattgtt agttttacag 
     1621 tgtgttgggt tgaagagaag caggcctacc ctagaagaag acaggactgg gaacattttg 
     1681 aggaaagggc agggcatttg gggtggtagt gagcttcagt ttagctacat ggaagccagg 
     1741 catggtatgc acagcacagt cctttaatac cggtgcttgg gaggcagagg aagagtgatt 
     1801 tcttctgagc caaggacagc ttggtctata catcaaattc cagaccaggt agggttccaa 
     1861 agggagatcc tgtctcaaag aaagaaatta gaccctgagt tggaggctca tagttctctg 
     1921 tgtaagctac cagagccccc agacttttgc tgtgggcact gatgttgcag ggctggcagc 
     1981 tgagtcccca tggcttgtga cctcaggaaa ctttgggtct ccttgggcac tggtgtggcc 
     2041 cattctattg gatggaagtt aaggcaggcc atgtggagtc aagagtgccg ctgaggtata 
     2101 cttctgacct cctggggcct tcggtacact tgccgccctt gttctcctgg agagctcttt 
     2161 acaggtggga tctcacttgg acacactatt gctgatagat tcctttgaag acgagaggca 
     2221 tccgtgtgct tattacttag tcactgcagc tggagtctat gtagcctgtt tggaaggacc 
     2281 agcttgctgc ctttcccagg ctccagatgg tagacagtac tagaaagggc acagggctca 
     2341 caggcttgga cagtgcccac tgtctctata ctcctggatg gtggtgagct tgtaagaacc 
     2401 cagcagttat gggagggagg atcagtattt gggtcaggac taggagttag caaatgagaa 
     2461 cgccttggct gcctggcgga gtatttgaaa ggtatcccag gatagaacag aggttgtggg 
     2521 ccagaggcta gcaaaaaaat ttggtttggc tcatagtttt tttgagtttt ggttgtcttt 
     2581 tgtttacttg tttgtttgtc tggctgtttt tttttttttt tttttttggg tggggttttt 
     2641 ttttcctttt ttttttcttt tccatttttt attaggtatt tagctcattt acatttccaa 
     2701 tgctatacca aaagtccccc atagccaccc acccccattt tttttccttt ttatctttta 
     2761 aattttaacc ttttagttta aaaaaatttg tgtgtgtgtg tgtgtgtgtg tgtgtgtaag 
     2821 tgtgggaaga ccagtcccgt ggggtgggtt tacgcctgga ctggccagct gccagtcatt 
     2881 tttgtaggtt ctctttgtga cctctgacct gtgaatgact tctttcatac ctgaaagagt 
     2941 aacaaaggaa aattcaaacc ccattaacat ttctagattt atttttatgt atgtgagtgc 
     3001 tttgcctgca tgtatataac tgcttgagtg cctgctgctt gcagagttaa taagagggca 
56 
     3061 tcagatcctg ggaatcagac ttacagatga tttgaagaac agcaagtgca cttagccaat 
     3121 aagccctcta cctagcctat acaccttggg ttttgcttgg cacctgtatt tgtcatgacc 
     3181 tctttttcca tgtgagtagt tggcaggaaa tgagaggaca cggtcttata cataatgaaa 
     3241 tctgtcctgt acactgtgcc tgaggagggt ggaatccggt gggctcagta cataccctgt 
 
     3301 gccaggcctt cgtgcaggtt gcaggttaac tatctatcCT GCCTGTTCTT GCCCACAGGT 
                                                                                                          L     P     V     L     A     H     R   
     3361 GGTGCCCGTG GGCAGGGCAC AGGGACATGG GGCCAGACAT GGAGCTTCCC AGCCATTCAA 
                  W    C     P     W     A     G     H     R     D     M     G     P     D     M     E     L     P     S     H      S     K   
     3421 AACAGCTCCT GCTACAGCTG AACCAGCAGA GGGCCAAGGG CTTCCTGTGT GACGTCATCA 
                      Q     L     L     L     Q     L     N     Q     Q     R     A     K     G     F     L     C     D     V     I     I       
     3481 TCATGGTGGA GAACTCTATC TTCCGGGCCC ACAAGAATGT CCTGGCTGCT AGCAGCATCT 
                      M    V     E     N     S     I     F     R      A      H       K      N      V      L      A      A      S      S      I 
     3541 ACTTCAAGTC CCTGGTCCTG CATGATAACC TCATCAACTT AGACACAGAC ATGGTCAGCT 
                          Y     F     K     S     L    V     L     H    D     N     L     I     N     L     D     T     D     M     V     S   
     3601 CCACTGTGTT CCAGCAGATC CTGGACTTCA TCTACACAGG CAAGCTCCTG CCCAGTGACC 
                          I      Y     T     G     S     T     V     F     Q     Q     I     L     D     F     K     L     L     P     S     D   
     3661 AGCCATCTGA GCCAAACTTC AGCACTCTAC TCACTGCTGC CAGCTACCTC CAGCTGCCTG 
                     Q     P     S     E     P     N     F     S     T     L     L     T     A     A     S     Y     L     Q     L     P 
     3721 AGTTGGCAGC CCTCTGTCGC CGCAAACTGA AGCGAGCTGG CAAGCCCTTT GGCCCTGGAC 
                         E      L     A     A     L     C     R     R     K     L     K     R     A     G     K     P     F     G     P     G 
     3781 GAGTGGGTAC TGCTGGCATA GGGCGACCAA CCCGCAGTCA GCGGCTGTCC ACAGCCTCTG 
                          R     V     G     T     A     G     I     G     R     P     T     R     S     Q     R     L     S     T     A     S 
     3841 TCATCCAGGC TCGATTTCCA GGGCTTGTAG ATGTGCGTAA AGGACACCCT GCTCCCCAGG 
                         V     I     Q     A     R     F     P     G     L     V     D     V     R     K     G     H     P     A     P     Q   
     3901 GCTCCCTCA GGCCAAAGGC TCAGATGATG AGCTTTTTCT GGGCACCTCC ACTCAGGAGA 
                         E     L     P     Q     A     K     G     S     D     D     E     L     F     L     G     T     S     T     Q     E   
     3961 GCACACACGG CCTGGGCTTG GGGGGTCCAG CTGGTGGGGA GATGGGCTTG GGGGGCTGCA 
                         S     T     H     G     L     G     L     G     G     P     A     G     G     E     M     G     L     G     G     C 
     4021 GCACCAGCAC CAATGGGAGT AGTGGGGGCT GTGAGCAGGA GCTGGGCTTG GACCTGTCCA 
                          S     T     S     T     N     G     S     S     G     G     C     E     Q     E     L     G     L     D     L     S 
     4081 AGAAGAGCCC ACCCTTACCT CCTACAACCC CTGGCCCCCA CCTCACACCC GAGGACCCAG 
                            K     K     S     P     P     L     P     P     T     T     P     G     P     H     L     T     P     E     D     P 
     4141 CCCAGCTGAG TGACAGCCAG CGAGAGTCAC CCGCACCCAC ATCGACCTCT GCCCTGCCTG 
                            A     Q     L     S     D     S     Q     R     E     S     P     A     P     T     S     T     S     A     L     P 
     4201 TCGGCAATAG TGCCTCATTT GTTGAGCTGG GGGCCACTCC TGAGGAGCCC ATGGATGTGG 
                           V     G     N     S     A     S     F     V     E     L     G     A     T     P     E     E     P     M     D     V   
     4261 AAGGGGCTGA GGAAAACCAC CTGAGTCTGC TGGAAGGACA GGGTGGGCAG CCTCGCAAGA 
                           E     G     A     E     E     N     H     L     S     L     L     E     G     Q     G     G     Q     P     R     K   
     4321 GCCTCCGGCA TTCAGCCCGC AAAAAAGATT GGAACAAAAA GGAACCTGTG GCTGGGTCCC 
                           S     L     R     H     S     A     R     K     K     D     W     N     K     K     E     P     V     A     G     S 
     4381 CCTTTGATAG GAGAGAAACA* GGATCTAAGG GTTCCTGCCC AGGGGAAGAA GTGAAGGGA 
                            P     F     D     R     R     E     T     G     S     K     G     S     C     P     G     E     E     G     E     G 
     4441 CTGGGGACAG GGTTCCCAAT GGCGTTCTGG CTAGCAGTGC TGGTGGAGGT GGCCCCAGTG 
                            T     G     D     R     V     P     N     G     V     L     A     S     S     A     G     G     G     G     P     S   
     4501 CATCGTATGG GGAGCAGTCA TTCCCCTGCA AGGAGGAGGA GGAGAATGGC AAAGATGGGA 
                            A     S     Y     G     E     Q     S     F     P     C     K     E     E     E     E     N     G     K     D     G 
     4561 GTGAGGACAG TGGGCAGAGT GGGAGTGAGG GGGGCAGCGG CCATACTGGC GCCCACTATG 
                       S     E     D     S     G     Q     S     G     S     E     G     G     S     G     H     T     G     A     H     Y 
     4621 TATACCGGCA GGAAGGCTAT GAGACAGTGT CATATGGGGA CAATGTTTAT GTGTGCATCC 
                           V     Y     R     Q     E     G     Y     E     T     V     S     Y     G     D     N     V     Y     V     C     I 
     4681 CCTGTGCCAA GGGCTTCCCC AGCTCTGAGC AGCTCAATGC TCACGTGGAG ACACACACGG 
                           P     C     A     K     G     F     P     S     S     E     Q     L     N     A     H     V     E     T     H     T 
     4741 AGGAGGAGTT ATTCATCAAG GAAGAAGGGG CTTATGAGAC CGGCAGTGGG GGTGCCGAGG 
                           E     E     E     L     F     I     K     E     E     G     A     Y     E     T     G     S     G     G     A     E 
     4801 AGGAGGCTGA GGACCTGTCA ACACCTAGTG CAGCCTACAC AGCTGACTCT CGTCCTTTCA 
                          E     E     A     E     D     L     S     T     P     S     A     A     Y     T     A     D     S     R     P     F 
 
     4861 AGTGCTCAGT TTGTGAGAAG ACCTACAAGG ACCCAGCCAC ACTGCGGCAA CACGAGAAGA 
                         K     C     S     V     C     E     K     T     Y     K     D     P     A     T     L     R     Q     H     E     K 
     4921 CACACTGGTT GACCCGTCCG TTCCCCTGCA ACATTTGTGG AAAGATGTTC ACACAGCGAG 
                         T     H     W     L     T     R     P     F     P     C     N     I     C     G     K     M     F     T     Q     R 
57 
     4981 GCACTATGAC ACGCCACATG CGGAGCCACC TGGGCCTGAA GCCCTTTGCC TGTGATGAGT 
                         G     T     M     T     R     H     M     R     S     H     L     G     L     K     P     F     A     C     D     E 
     5041 GTGGTATGCG TTTCACTCGC CAGTACCGCC TCACAGAGCA CATGCGTGTG CACTCAGGTG 
                         C     G     M     R     F     T     R     Q     Y     R     L     T     E     H     M     R     V     H     S     G 
     5101 AGAAGCCCTA TGAGTGCCAG CTCTGTGGAG GCAAGTTCAC CCAACAGCGC AACCTCATCA 
                          E     K     P     Y     E     C     Q     L     C     G     G     K     F     T     Q     Q     R     N     L     I 
     5161 GCCACCTGCG CATGCACACT TCCCCTTCCT AGaagccaaa GACCCGTGGG AGCCCTCTAC 
                          S     H     L     R     M     H     T     S     P     S   
     5221 AGACTTGCCA CTTGGGAACC CACGGAAGCA TGGTGGGAGG GTTGAGCCCC AAAGTCTGAC 
     5281 ATGAGGCTCC TGGCAGCCCC TCTGGCCCAG CCTCCTCACG CCCAGAGCTT TAATCAACAG 
     5341 TATACCAAGG GAAGCCAAGA GAGAAGCTGA CCAGTCTAGC CCTATGCATG TGGTGCTGGT 
     5401 GACTATTCTA CCTCCCTGGG CCCACTGGGC TTTCCAGCTC CCTGAAGGAG CTGCTGAAGA 
     5461 GCCGGTGGGA GTCCATCATG TGGGTGCCAG TGGGGCCTGG TTGGTTCCTT TCCTGCAGGT 
     5521 TGGGCTGGGC CACAGGGTTT CCTGTGGCCA AAAGTGGTGC CTGGAGCAGG CCTAGCTGGC 
     5581 AGGGACCTCG GCTGTGTGTG TGCATGTGTG CTTGTGTCTT TGCAGTGCAG TGTGACTCTG 
     5641 GTGTTGGGGT GCTGGTGCTG GGTGGCAGTT CCTTTCTCTG TGAGCTGGGG TGGCAACTGC 
     5701 TAGCTGGCAC TGGAACAGTC AGGGTGACCC ATTGCCTACC TCTCTGCAAC TAAAGAGCCC 
     5761 TCTGGGCCTA TATTGCTGTT ATTCCTACTG AGCTGTTCCT ATTTCTTTTT TACAGTTTTT 
     5821 AAAAATTCTT TTTTAAAACC AAAATGAACA ATATTTTCCT CCTGCCTCTT TGGGGTTGAG 
     5881 CCTGGGTCTG CAGACTGAAT GTAACCGGGG CAGCTGCCCC TCCCTATCAT TTTCCCTAGT 
     5941 CCTGGTGCTT GGGCATGGTT GAACCTGCCT CTCCAAGGCC CAGAAGCCCT TCTTGCCCAA 
     6001 AGGCTTCCCT GATTCTGAGC CCTGCCTGCC TGGGCTTCCT CAGGAGAATA TGCTTTTCCA 
     6061 TAATTTCCAA GGAATGTCCC TTGTTAGAGG TACTTATTTT TATTGAGAAC CACACCCTCC 
     6121 CCCATATACC TTTTTGAGAT GTGGAACTGG AAGGTCTGAA GTTTCAGAGG GTGGAGGGGA 
     6181 GGCTAGATTC GGTGCCAGAG CCATCGGTAC TCTTGCTCTC GTGTGCACAC  
     6301 GCGCGCGCAT GTGCGTGTGT GTTGCTTATG CACAGATGCT TCACTTCCTT  
 
 
 
Figure 3.6  Hic2 genomic DNA and deduced amino acid sequence. The deduced amino acid sequence 
is shown below the nucleotide sequence of the DNA. The BTB/POZ domain is blue coloured, the C-
terminal zinc fingers are shown in bold and underlined. The cluster of basic amino acids (R R K L K R 
A G K) is underlined and GLDLSK is shown in bold. The TATA box is red coloured. The recognition 
sites for known transcriptions factors in the 5’UTR are underlined and green coloured. Possible start 
codons (ATG) are underlined, stop codon (TAG) is red coloured, position of the known cDNA 
sequence (Grimm), position 4440 is marked with *.  
The coding sequences, exons and 3’UTR are indicated as capital letters, intron sequences are shown as 
lower case letters. Repetitive TG and TC sequence in 3’UTR (Microsatellite) is underlined. PolyA-tail 
is underlined. Abbreviations : GKLF, Gut-enriched Krüppel-like factor, EVI1, Ecotropic viral 
integration site 1 encoded factor, SP1, Stimulating protein1, ubiquitous zinc finger transcription factor, 
WT1, Wilms Tumor Suppressor, AP4, Activator protein 4, p53, Tumor suppressor p53, CCAT box, 
cellular and viral CCAT box, ZBP-89, Zinc finger transcription factor 89. 
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  3.3 Deduced amino acid sequence and domain structure 
 
The deduced Hic2 protein consists of 601 amino acids including a POZ domain and five 
C2H2 zinc fingers at the C terminus (Fig. 3.7). Following the POZ domain, Hic2 contains a 
cluster of basic amino acids, RRKLKRAKK (Fig. 3.6). 
Database searches with mouse Hic2 protein sequence revealed similarities to the human HIC2 
protein, chicken γF-crystallin binding protein (γFBP), mouse Hic1 and human HIC1 protein 
(Fig. 3.7). Similar to Hic2 and HIC2, γFBP encodes also a protein with a BTB/POZ domain, 
five zinc fingers and a short, conserved GLDLSK/K motif. Comparison among Hic1, HIC1 
and γFBP proteins showed more or less identity , to better appreciate the relationship among 
the Hic2 and Hic1 proteins from various species a multiple alignment using the CLUSTAL 
program was generated (Fig.3.7). 
 
Multiple alignment analysis highlighted two regions of strong conservation between Hic2 and 
Hic1 to the BTB/POZ and Zinc fingers domains (Fig. 3.7 and 3.8). 
Regarding the BTB/POZ domain, the first 87 residues are well conserved. The 3’ part of the 
BTB/POZ domain is less conserved . 
 
A short GLDLSK polypeptide located in the central region between BTB/POZ and zinc finger 
domain is perfectly conserved (Fig.3.7 and 3.8). The GLDLSK sequence identity between 
Hic2 and human HIC2, zebrafish HRG22, chicken γFBP-B, mouse Hic1 and human HIC1 
protein was 100%. 
 
The zinc fingers domain was more highly conserved than the central region. It is split into five 
parts; the more upstream zinc finger 1, and the downstream zinc fingers 1-4. This C-terminal 
end appears globally more highly conserved 70%.  The upstream zinc finger motif is present 
and well conserved. The four C-terminal C2H2 zinc fingers are separated by a typical 7- to 8-
amino-acid conserved link, the H/C link found in Krüppel-like zinc fingers and are thus likely 
to be involved in sequence-specific DNA-binding. 
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Multiple alignment 
 
Hic2         ----------------------------------------------------------MG 
HIC2         ----------------------------------------MVSGPLALRWCAWAGRGDMG 
Hic2ZF       ------------------------------------------------------------ 
GammaFBP     ---------------------APGARPAA--SRERGHKSREERCGERGAAAGRRARGAML 
Hic1         RGGAETRPGRGEDGPARQTDRGPGGRRAAHCSHVPPWIRRQPGPGLPTCPPGECAGQMML 
HIC1         ----------------------------------------------------------ML 
 
                                        BTB/POZ 
Hic2         PDMELPSHSKQLLLQLNQQRAKGFLCDVIIMVENSIFRAHKNVLAASSIYFKSLVLHDNL 
HIC2         PDMELPSHSKQLLLQLNQQRTKGFLCDVIIMVENSIFRAHKNVLAASSIYFKSLVLHDNL 
Hic2ZF       --MELPNHAKQLLLQLNQQRAKGYLCDVIIVVENALFRAHKNILAASSIYFKSLILHDNL 
GammaFBP     EAMEVPSHSRQLLLQLNTQRTKGFLCDVIIVVQNALFRAHKNILAASSAYLKSLVVHDNL 
Hic1         DTMEAPGHSRQLLLQLNNQRTKGFLCDVIIVVQNALFRAHKNVLAASSAYLKSLVVHDNL 
HIC1         DTMEAPGHSRQLLLQLNNQRTKGFLCDVIIVVQNALFRAHKNVLAASSAYLKSLVVHDNL 
 
     BTB/POZ 
Hic2         INLDTDMVSSTVFQQILDFIYTGKLLPS---------DQPSEPNFSTLLTAASYLQLPEL 
HIC2         INLDTDMVSSTVFQQILDFIYTGKLLPS---------DQPAEPNFSTLLTAASYLQLPEL 
Hic2ZF       INLDTDMVNPSVFRQVLDFIYTGKLLSS---------DQFSDHNFNALLTAASYLQLHDL 
GammaFBP     LNLDHEMVSPGIFRLILDFIYTGRLGE---------CEPGGEQSLGAVLAAASYLQIPGL 
Hic1         LNLDHDMVSPAVFRLVLDFIYTGRLTDSVEAAAAAAVAPGAEPSLGAVLAAASYLQIPDL 
HIC1         LNLDHDMVSPAVFRLVLDFIYTGRLADGAEAAAAAAVAPGAEPSLGAVLAAASYLQIPDL 
 
 
Hic2         AALCRRKLKRAGKPFGPGRVGTAGIGRPTRSQRLSTASVIQARFPGLVDVRKGHPAPQEL 
HIC2         AALCRRKLKRAGKPFGSGRAGSTGMGRPPRSQRLSTASVIQARYQGLVDGRKGAHAPQEL 
Hic2ZF       AALCRKKLKRNGRSL-LNKPTTPTNGRTSRNQRLSSTPVTPNQMSGLKDSEK-TKRHEEL 
GammaFBP     VALCKKKLKRSGKYCHLRGG------YAPY-KLGRGLRATTPVIQACYSGT----PRPVD 
Hic1         VALCKKRLKRHGKYCHLRGGGSGGGGYAPYGRPGRGLRAATPVIQACYSSPAGPPPPPAA 
HIC1         VALCKKRLKRHGKYCHLRGGGGGGGGYAPYGRPGRGLRAATPVIQACYRSPVGPPPPPAA 
 
 
Hic2         PQAKGSDDELFLGTSTQESTHGLGLGG-PAGGEMGLGGCSTSTNGSSGGCE-QELGLDLS 
HIC2         PQAKGSDDELFLGGSNQDSVQGLGRAVCPAGGEAGLGGCSSSTNGSSGGCE-QELGLDLS 
Hic2ZF       IKDDLSEDEMFARNTHCTTSNSLSP--------------STSKNGSNGSCGMQELGLDLS 
GammaFBP     LQPVEPAAPL---NTQCGELYASASQGTP--------LHPHGLCPPERHCS-PPCGLDLS 
Hic1         EPPSGPDAAV---NTHCAELYASG----P--------GPAASLCAPERRCS-PLCGLDLS 
HIC1         EPPSGPEAAV---NTHCAELYASG----P--------GPAAALCASERRCS-PLCGLDLS 
 
 
Hic2         KKSPPLPPTTPGPHLT---PEDPAQLSDSQRESPAPTSTSALPVGNSASFVELGATPEEP 
HIC2         KKSPPLPPATPGPHLT---PDDAAQLSDSQHGSPP--AASAPPVANSASYSELGGTPDEP 
Hic2ZF       KKSPSGSTATE--EVS---PSSIPQESPQSASESTANSASFDENPNTQNL-----TAGEP 
GammaFBP     KKSPTGPSAQLLPTDRLLPAEPREPSLPPRHDSPPVSGGLLAGHPAAYKDSPPGGEPGGH 
Hic1         KKSPPGSSVPERPLS--------ERELPPRPDSPPGAGPAVYKEPSLALPPLPPLPFQKL 
HIC1         KKSPPGSAAPERPLA--------ERELPPRPDSPPSAGPAAYKEPPLALPSLPPLPFQKL 
 
Hic2         MDVEGAEENHLSLLEGQGGQPRKSLRHSARKKDWNKKEPVAGSPFDRRETGSKGSCPGEE 
HIC2         MDLEGAEDNHLSLLEAPGGQPRKSLRHSTRKKEWGKKEPVAGSPFERREAGPKGPCPGEE 
Hic2ZF       MELGVGECEESQ--PPPDVDQHKSSRQVTRQRRQPKSEGKKGEDMER-VTLPNGV--SKR 
GammaFBP     PHAT---DPFRSTPPCAEPPLP-RGDGRELMYRWMKHEP-LGPYLDE------GEAEKEL 
Hic1         EEAVPTPDPFRGSGGSPGPEPPGRPDGSSLLYRWMKHEPGLGSYGDE-LVRDRGSPGERL 
HIC1         EEAAPPSDPFRGGSGSPGPEPPGRPDGPSLLYRWMKHEPGLGSYGDE-LGRERGSPSERC 
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Hic2         GEGTGDRVPNGVLASSAGGGGPSASYGEQSFPCKEEEENGKDGSEDSGQSG-SEGGSGHT 
HIC2         GEGVGDRVPNGILAS---GAGPSGPYGEPPYPCKEEEENGKDASEDSAQSG-SEGGSGHA 
Hic2ZF       LKVAGERLPAG-------GNGNS----EVSFQCKDEEEGLENGQEQSEESGQSENEGGRN 
GammaFBP     ERE--EKAESPPA-----APQPRYPSV-----ESNDLEPDNSTSEETGSSEGPSP-GDAL 
Hic1         EERGGDPAASPGGPPLGLVPPPRYPGSLDGPGTGADGDDYKSSSEETGSSEDPSPPGGHL 
HIC1         EERGGDAAVSPGGPPLGLAPPPRYPGSLDGPGAGGDGDDYKSSSEETGSSEDPSPPGGHL 
                                            
                                           
                                            ZF1 
Hic2         GAHYVYRQEGYETVSYGDNVYVCIPCAKGFPSSEQLNAHVETHTEEE--LFIKEEGAYET 
HIC2         SAHYMYRQEGYETVSYGDNLYVCIPCAKGFPSSEQLNAHVETHTEEE--LFIKEEGAYET 
Hic2ZF       SANYVYRQEGFEP-ALGDNLYVCIPCGKGFPSSEELNAHVETHTEEE--LYIKEEDD-DS 
GammaFBP     DRY-CNHLGY-EPESLGDNLYVCIPCGKGFPSSEQLNAHVEAHNEEE--LYHKAAAEQAV 
Hic1         EGYPCPHLAYGEPESFGDNLYVCIPCGKGFPSSEQLNAHVEAHVEEEEALYGRAEAAEVA 
HIC1         EGYPCPHLAYGEPESFGDNLYVCIPCGKGFPSSEQLNAHVEAHVEEEEALYGRAEAAEVA 
 
                                                     ZF2 
Hic2         ----GSGGAEEEAEDLSTP-SAAYTADSRPFKCSVCEKTYKDPATLRQHEKTHWLTRPFP 
HIC2         ----GSGGAEEEAEDLSAP-SAAYTAEPRPFKCSVCEKTYKDPATLRQHEKTHWLTRPFP 
Hic2ZF       ----YPKEDEVEAEDLSSQITQVHGTETRRFSCSVCNKSYKDPATLRQHEKTHWLTRPFP 
GammaFBP     -------PFLDKGG-------AGLGDILRPYRCSSCDKSYKDPATLRQHEKTHWLTRPYP 
Hic1         AGAAGLGPPFGGGGDKVTGAPGGLGELLRPYRCASCDKSYKDPATLRQHEKTHWLTRPYP 
HIC1         AGAAGLGPPFGGGGDKVAGAPGGLGELLRPYRCASCDKSYKDPATLRQHEKTHWLTRPYP 
 
                     ZF3                             ZF4 
Hic2         CNICGKMFTQRGTMTRHMRSHLGLKPFACDECGMRFTRQYRLTEHMRVHSGEKPYECQLC 
HIC2         CNICGKMFTQRGTMTRHMRSHLGLKPFACDECGMRFTRQYRLTEHMRVHSGEKPYECQLC 
Hic2ZF       CNICGKMFTQRGTMTRHMRSHLGLKPFACEECGMRFTRQYRLTEHMRVHSGEKPYECQLC 
GammaFBP     CTICGKKFTQRGTMTRHMRSHLGLKPFACDACGMRFTRQYRLTEHMRIHSGEKPYECQVC 
Hic1         CTICGKKFTQRGTMTRHMRSHLGLKPFACDACGMRFTRQYRLTEHMRIHSGEKPYECQVC 
HIC1         CTICGKKFTQRGTMTRHMRSHLGLKPFACDACGMRFTRQYRLTEHMRIHSGEKPYECQVC 
 
                    
                   ZF5 
Hic2         GGKFTQQRNLISHLRMHTSPS--------------------------------------- 
HIC2         GGKFTQQRNLISHLRMHTSPS--------------------------------------- 
Hic2ZF       GGKFTQQRNLISHLRMHTSPS--------------------------------------- 
GammaFBP     GGKFAQQRNLISHMKMHAAG--------------------PDGKAKLDFPDSVYAMARLT 
Hic1         GGKFAQQRNLISHMKMHAVGGAAGAAGALAGLGGLPGVPGPDGKGKLDFPEGVFAVARLT 
HIC1         GGKFAQQRNLISHMKMHAVGGAAGAAGALAGLGGLPGVPGPDGKGKLDFPEGVFAVARLT 
 
 
 
 
 
 
 
 
Figure 3.7 Comparison of mouse Hic2 related proteins. Multiple alignment of mouse Hic2, human 
HIC2, chicken γFBP, zebrafish HRG22, mouse Hic1 and human HIC1 proteins. Sequences were 
aligned with Swissprot Expassy CLUSTAL protein alignment program. The BTB/POZ and zinc finger 
domains are boxed. The RRKLKRAGK cluster of basic amino acids is underlined, the GLDLSK 
polypeptide is red coloured, the upstream zinc finger ZF 1 is boxed, like the downstream zinc fingers 
ZF2, ZF3, ZF4 and ZF 5. 
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                                                 POZ/BTB GLDLSK   Zf 1            Zf 2-5 
Hic2                                                                                                                                 601 AA 
                                                       72%             100%        100%               100% 
HIC2                                                                                                                                615 AA 
                                                   61%      100%         88%              95% 
Hic2zebrafish                                                                                                                  560 AA 
                                                 50%       100%         94%              83%                                 
γFBP-B                                                                                                                           676 AA 
                                                49%         100%       93%                    81% 
Hic1                                                                                                                                 892 AA 
                                                         41%        100%         93%              81% 
HIC1                                                                                                                                714 AA 
 
 
 
Figure 3.8 Domain structure. Schematic representation of the predicted mouse Hic2, human HIC2, 
chicken γFBP, zebrafish HRG22, mouse Hic1 and human HIC1 proteins. 
Degrees of conservation (% of identity) obtained with the NCBI BLAST search program are indicated. 
Sequence accession numbers are for mouse Hic2 protein NP 849253, AF 117382, human HRG22 
(HIC2) protein XP 036937, chicken γFBP-B protein Q 90850, zebrafish HRG22 (HIC2) protein NP 
878289, mouse Hic1 protein NP 006488 and  human HIC1 protein NP 006488. The Hic2 BTB/POZ 
domain sequence showed 72% identity with human HIC2, 61% identity with zebrafish Hic2, 49% 
identity with chicken γFBP-B protein, 49% identity with mouse Hic1 and 41% identity with human 
HIC1 sequence. The Hic2 protein zinc finger 1 (ZF1) sequence showed 100% identity with human 
HIC2, 88% identity with zebrafish Hic2, 94% identity with γFBP-B protein, and 93% identity with 
mouse Hic1 and human HIC1. The Hic2 protein zinc finger 2 (ZF2) sequence showed 100% identity 
with human HIC2, 90% identity with zebrafish Hic2, 81% IDENTITY WITH γFBP-B protein, 77% 
identity with mouse Hic1 and human HIC1. The Hic2 protein zinc finger 3 (ZF3) sequence showed 
100% identity with human HIC2, 90% identity with zebrafish Hic2, 81% identity with γFBP-B 
protein, 77% identity with mouse Hic1 and human HIC1.The Hic2 protein zinc finger 4 (ZF4) 
sequence showed 100% identity with human HIC2 and zebrafish Hic2 and 90% identity with γFBP-B 
protein, mouse Hic1 and human HIC1. The Hic2 protein zinc finger 5 (ZF5) sequence showed 100% 
62 
identity with human HIC2 and zebrafish Hic2 and 80% identity with γFBP-B protein, mouse Hic1 and 
human HIC1 protein. 
 
Following the structure of conserved domains it is clear that is a more homology between 
mouse Hic2 and human HIC2 including the zebrafish Hic2 sequence, and on the other side 
there is a more homology between mouse Hic1 and human HIC1. 
 That’s why we can say there are two protein subgroups in the same family. Chicken γFBP-B 
showed more homology with Hic1 subgroup (Fig.3.9).  
 
 
 
 
 
                       
 
 
 
 
 
Figure 3.9 The phenogram of protein family members. A branching diagram that links entities by 
estimates of overall similarity. There are two sub group of the family members Hic1 and human HIC1, 
Hic 2 and human HIC2 including the zebrafish Hic2 protein. 
 In the sequence identities γFBP-B showed more identity with sub group Hic1/HIC1. Till now there 
are known various species (human, mouse, zebrafish, chicken) with the same protein family, which are 
coding the same, important, conserved domains.   
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3.4 Characterization of the Hic2 promoter 
 
3.4.1 Binding sites and deletions constructs in the Hic2 promoter 
 
The computer program PromoterInspector (http://genomatix.gsf.de) is designed for location 
of regulatory regions within long genomic sequences. However this program can not predict 
all promoters.  
For the location of potential binding sites but in short sequence stretches with known 
regulatory function, the MatInspector Professional (http://genomatix.gsf.de) was used.  
This program predicted a few  binding sites for gene regulation: Gut-enriched Krüppel-like 
factor, Stimulating protein 1 (SP1), Ecotropic viral integration site 1, Zinc finger transcription 
factor ZBP-89, AREB6 (Atp1a1 regulatory element binding factor 6), Wilms Tumor 
Suppressor, p53 and glucocorticoid receptor, C2H2 zinc finger protein binds glucocorticoid 
dependent to GREs (Fig.3.10A).  
 
Therefore a 1.2 kb fragment directly upstream of the Hic2 coding was cloned, in front of a 
Luc reporter gene (Y.Kamachi, 1993), (Fig. 3.10B). 
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Figure 3.10 Binding sites and deletion constructs in the Hic2 promoter. 
A) Binding sites predicted with MatInspector program. 1)  Gut-enriched Krüppel-like factor and 
Ecotropic viral integration site 1 encoded factor; 2) stimulating protein 1 SP1, ubiquitous zinc 
finger transcription factor and Wilms Tumor Suppressor and tumor suppressor p53 binding 
site; 3) cellular and viral CCAAT box; 4) Zinc finger transcription factor ZBP-89 and Wilms 
Tumor Suppressor; 5) AREB6 (Atp1a1 regulatory element binding factor 6); 6) 
Glucocorticoid receptor, C2H2 zinc finger protein binds glucocorticoid dependent to GREs. 
 
B) Deletions constructs of the Murine Hic2 promoter. PCR primers used for amplification of the 
genomic sequence are given in TABLE 2.14. 1-6 positions of binding sites, PR-R for reverse 
primer, L1-L5 for forward primers, P1-P4 for promoter fragments with deletion and P5 for 
total fragment without deletion. P1 385 bp, P2 424 bp, P3 518 bp and P4 685 bp. Total 
fragment without deletion P5 1167 bp. 
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Hic2 promoter sequences were PCR amplified (Fig.3.11 A); Forward primers contain an XhoI 
site for cloning, whereas the reverse PCR primer has a BamHI restriction site.  
These were cloned in to the pCR.IITOPO Vector, and recovered from the vector with 
BamHI/XhoI digestion (Fig.3.11 B).  
The fragments were cloned into the cloning site of the pPLLucII reporter vector (Y.Kamachi, 
1993), using SalI/BamHI and HindIII restriction enzymes (Fig.3.11 C). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11B. The PCR products were cloned and recovered from the pCR.IITOPO Vector with 
BamHI/XhoI enzymes.  
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Figure 3.11 A) The Hic2 promoter deletions PCR products. All five deletions were done with same 
forward primer IEX1-1D, reverse primers are located between the binding sites. 1) deletion 4 
(primers  IEX1-1D/IEX16L) 685bp, 2) deletion 1 (primers IEX1-1D/PromL1) 385 bp, 3) deletion 2 
(primers IEX1-1D/IEX1-3L) 424 bp, 4) total fragment without deletion (primers IEX1-1D/IEX1-
7L) 1167bp, 5) deletion 4 (primers IEX1-1D/IEX1-6L) 685 bp. 
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Fig.3. 11 C. BamHI/HindIII digestion from pPLLucII. II Vector 
 
 
 
For transfection experiments, the HEK-293 (human embryonic kidney cells) cell line was 
used. This cell line can be used as a basic transfection system (Lengler and Graw, 2001).  
 
 
3.4.2 Hic2 promoter activity 
 
Fragments within the 1.2 kb fragment (385bp, 424bp, 581bp, 685bp and 1167bp), result in a 
different promoter activity (Fig.3.12). The transfection of the Hic2 promoter constructs in 
HEK-293 fibroblast cell line was done three times under the same conditions.  
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Figure 3.12 Function of Hic2 promoter fragments. The peak activity of the Hic2 promoter is located in 
construct number five (-894/+13, total fragment without deletion), the next higher activity is in the 
deletion number two (-715/+13). The relative Luciferase activity for column 1 control 0/0 is 1, for 
fragment 1 is 0.6611, for fragment 2 is 1.3849, for fragment 3 is 0.8957, for fragment 4 is 1.0836 and 
for total fragment column 5 is 1.4086. 
 
 
 
 
Cutting the promoter sequence only 385 bp of its 3’ end showed the lower activity but its 
activity drops down to the level of the promoter-less reporter plasmid. It is obvious that the 
365bp fragment number one has the lowest activity (-796/+13). This deletion is just upstream 
from the TATA box and coding nine Gut-enriched Krüppel-like factor binding sites and nine 
Ecotropic viral integration site 1 encoded factor binding sites. 
 
The fragment number 2 (-715/+13) which included proximal binding sites in 3’ of the 
promoter (GEKL and Evil1) and 4 binding sites from stimulating protein 1 SP1, ubiquitous 
zinc finger transcription factor and Wilms Tumor Suppressor and tumor suppressor p53 
binding site, showed increased promoter activity.  
1 2 3 4 5 6
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This deletion showed already after deletion five the highest activity in the cell culture. But we 
can not exclude binding factors from the first deletion. Obviously alone in the construct 
(deletion1), binding factors are not active but with binding sites from Wilms Tumor 
Suppressor and tumor suppressor p53 binding site, which should play a big role in the Hic2 
activation, (tumor suppressor function), activation is higher. This part (deletion 2) could be 
essential for the function of the Hic2 gene. 
 
The fragment number 3 (-654/+13) showed decreased activity. This construct include the 
binding sites from deletion 1 and cellular and viral CCAAT box. This transcription factor 
(cellular and viral CCAAT box) should have a suppressor effect in this deletion construct. 
 
 Fragment number 4 (-395/+13) showed high activity. This construct included binding sites 
from deletion one to three and for Zinc finger transcription factor ZBP-89 and Wilms Tumor 
Suppressor and AREB6 (Atp1a1 regulatory element binding factor 6). It showed a direct 
connection between those binding factors and promoter activity. 
  
The total fragment without deletion (5), (-894/+13), included all binding sites and the 
Glucocorticoid receptor, C2C2 zinc finger protein binds glucocorticoid dependent to GREs 
which is specific just for this construct and  showed the highest activity.  
 
Because of the binding sites in the of the promoter (Zinc finger transcription factors, Wilms 
Tumor Suppressor and tumor suppressor p53 binding site, involved in tumor- and 
cancerogenesis) this part could be essential for the function of the Hic2 promoter.  
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3.5 Expression of the mouse Hic2 mRNA 
 
The expression of the mouse Hic2 was investigated by in situ hybridisations (ISHs) of whole 
mount embryos and on paraffin sections.  
As templates for riboprobes, the 576bp and 449bp, Hic2 mRNA clone AF117382, and 300bp 
cDNA clone from the Exon 2 were used. No obvious differences were observed in the 
expression patterns detected by riboprobes generated from both templates.  
No expression was observed in the earliest stages investigated, Theiler stages (TS) 12-14 (day 
8-9 p.c.).  
At later stages, Hic2 expression was detected in restricted territories of brain, sinus centralis, 
olfactory bulb, canallis centralis medullae spinalis, embryonic ectoderm (neuroepithelium of 
neural tube), small intestine.  
RT-PCR analysis showed tissue-specific expression of the Hic2 probe. Expression was strong 
in adult organs, especially in the brain.  
 
3.5.1 The whole mount In-situ hybridisation (WMISH) 
 
The RNA In situ hybridisation was done on whole mount embryos. As positive control for 
whole mount in situ hybridisation an En1 probe was used. This probe is characteristically 
expressed in the brain in the earlier stages of mouse development (TS13), and in the limbs and 
somites in later stages (TS 14-18) (Fig. 3.13). 
In mouse embryo the expression of this gene was first detected at E8 in overlapping bands of 
the anterior neural folds. 
By E12, the gene was expressed in a ring of cells in the central nervous system at 
midbrain/hindbrain junction En-1 was also expressed in two lateral stripes extending the 
length of the hindbrain and spinal cord in the developing vertebral column and in the tail and 
limb buds. These data are consistent with En-1 gene playing a role early in development in 
defining spatial domains in the CNS (Joyner and Martin, 1987). 
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Figure 3.13 En-1 probe with characteristic patterns.  
The embryos are in the Theiler stage (TS) 17, gestational age E11.5. 1) for brain, 2) for distal part of 
the limbs, 3) somite derivate and distal arch. 
 
 
 
3.5.2. Hic2 is expressed in the central and peripheral nervous system 
 
From Figure 3.14 , it is evident that Hic2 is expressed in a variety of tissue and organs like  
different parts of the brain, embryonic ectoderm (neural plate, neural channel and neural 
tube), in the limbic region of the brain, lateral ventrical of the olfactory lobe (lobe of the brain 
that rests on the lower surface of a temporal lobe and projects forward from the anterior lower 
part of each cerebral hemisphere, that is continuous anteriorly with the olfactory nerve, that 
consists of an olfactory bulb, an olfactory tract, and an olfactory trigone, and canallis centralis 
of the spinal cord (Fig. 3.14). 
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Figure 3.14 The embryos are Theiler stage (TS) 17, gestational age E11.5.  A) Hic2 is expressed in (1) 
sinus centralis, (2) myelencephalon, (3) metencephalon, (4) mesencephalon, (5) diencephalons, (6) 
telencephalon, (7) infundibulum, (8) pons, (9) canallis centralis medullae spinalis, and (10) small 
intestine. Hic2 expression is high present in the nervous system. (A) lateral views, (B) dorso-lateral 
views. Proximal but suprarostral part of the brain showed the highest level of expression. Cranio-
apical part is separated from the median part of the head in the region near the infundibulum and pons. 
This area which is more medially located showed no expression. Caudal part of spinal cord (9) in the 
ectoderm from the region of gluteal musculature showed expression.  
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Figure 3.14 B) Sense Hic2 probe  
 
 
 
3.5.3 Hic2 is expressed in the limbic region of the brain 
 
Transverse sections of the head TS24 (E17.5), showed Hic2 expression in the olfactory bulb. 
(Fig.3.15).The olfactory bulb is located in the limbic region of the brain. Each olfactory bulb 
is located on either side of the nasal passage at the base of the brain. They lie on a perforated, 
thin layer of bone that separates the nasal cavity from the brain.  
The function of the olfactory bulb is to relay sensory signals to the olfactory tract. The 
olfactory tract   contains axons from some of the neurons in the olfactory bulb. Some of those 
axons go directly to the phylogenetically oldest part of the cerebral cortex where they 
synapse, others travel through the anterior commissure to the contra lateral (opposite side) 
olfactory bulb. 
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Hic2 expression in olfactory bulbs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15 Transverse section (Theiler stage 24, E17.5). Expression is located in the olfactory bulbs 
(A) 1 ringed in red, 2 for nasal cavity and 3 for eye. (B) and (C) for higher magnification, 1 expression 
in the olfactory bulbs, (CP) cartilage primordium of the nasal septum, (ON) olfactory nerves, (NC) 
nasal capsule. 
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3.5.4 Hic2 is expressed in the embryonic ectoderm 
 
 
In whole body sagittal sections at TS 19, (gestational age E12.5) Hic2 expression in the 
ectoderm was detected. 
 The ectoderm produces the nervous system, the neural plate, the  neural channel and the 
neural tube. Hic2 is expressed in suprabasal layers of the caudal part of the neuroepithelium in 
a part characteristic for gluteal muscle development (Fig.3.16).  
 
The mouse embryo comprises three tissue layers, two extra-embryonic, the visceral endoderm 
and the extra-embryonic ectoderm, and one embryonic, the epiblast. At E5.5 a small subset of 
visceral endodermal cells, the anterior visceral endoderm (AVE), becomes morphologically 
distinct from the rest of the visceral endoderm and expresses a characteristic set of molecular 
markers. These cells are initially located at the distal tip of the embryo and then move up 
unilaterally to the prospective anterior converting the proximal-distal axis of the embryo into 
an anterior-posterior axis (Rodriguez et al., 2002). 
 During gastrulation in vertebrates the cells of the embryonic ectoderm give rise to epidermal 
progenitors in the ventral side and neural progenitors in the dorsal side (Chang et al., 1998). 
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Hic2 expression in embryonic ectoderm 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17  Sagittal sections of the embryos Theiler stage 19, Carnegie stage 16, gestational stage 
E12.5.  
Caudal part of the body, region near the tail and gluteal musculature. (A) and (B) for lower 
magnification, (C) and (D) for higher magnification. EE embryonic ectoderm, HD horda dorsalis 
Expression is obvious in granular layer of the ectoderm.  
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3.5.5 Hic2 is expressed in small intestine 
 
The duodenum is the first part of the small intestine. It is located between the stomach and the 
jejunum. The jejunum and ileum are suspended from the posterior abdominal wall by the 
mesentery of the small intestines. The jejunum occupies a central position in the abdominal 
cavity, below the liver and the stomach, and behind the transverse mesocolon, the transverse 
colon and the greater omentum. The ileum is the posterior or lower part of the small intestine. 
The Hic2 is expressed in the small intestine, duodenum, ileum and jejunum (Fig. 3.18). 
 
 
 
 
 
 
 
Figure 3.18. Sagittal section abdomen  TS24,(gestational age E17.5). (AS) for anti sense probe with 
expression. (S) for control sense probe. 1. Lumen of first part of duodenum, 2.small intestine, 3. Liver, 
no expression found 4. Lumen of bladder (orientation). 
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3.5.6 Hic2 is not expressed in eye 
RT-PCR analysis showed Hic2 expression in the eye TS24, E17.5 (Fig.3.19). That was a 
reason to test the gene at different developmental stages. 
 
  
                
 
 
Figure 3.19  RT-PCR results : 1) K-, 2)E12.5 head, 3) E12.5 body 4) E13.5 whole body and 5) E17.5 
eye. The expression in the eye was found just per RT-PCR analysis; ISH analysis on the section of the 
eye in different embryonic development stages was negative.  
 
Eye specific control probes with specific expression patterns were included:  CrygD probe 
which is expressed in the lens, Pax6 expressed in neural part of the retina and Pax2 expressed 
in nervus opticus of the eye (Fig.3.20).  
CrygD is specifically expressed in the eye lens (Lengler and Graw, 2001).  
Pax6 expression predominate in lens placode and corneal and conjunctival epithelia, in lens 
placode, optic vesicle and CNS, and only weakly in corneal and conjunctival epithelia (Xu et 
al., 1999). 
In the eye, Pax2 expression is restricted to the ventral half of the optic cup and stalk and later 
to the optic disc and nerve (Norens et al., 1990).  
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Expression of the mouse Hic2 gene in lens at embryonic, or fetal stages by means of in-Situ 
hybridisations of whole embryos and on paraffin sections was not detected (Fig.3.21).  
Thus, it is not likely that the Murine Hic2 gene is implicated in lens differentiation.  
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Figure 3.20 In situ hybridisation to assay CrygD, Pax6 and Pax2: 1) E11.5, 2) E12.5, 3) E13.5, 4) 
E14.5 and 5) E17.5 , 6)E15.5 Pax6 probe and  7) E15.5 Pax2 probe L  lens, R retina and N nervus 
opticus. 
 
CrygD, Pax6 and Pax2 were used because of the specific expressionpattern. L lens, R retina and N is 
for nervus opticus. 
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Figure 3.21 In situ hybridisation to assay Hic2 expression. 1) E11.5, 2) E13.5, 3) E15.5, 4) E17.5. 
Hic2 probe from 3’UTR with expression in the brain and intestine gave no results in the eye. c) and d) 
showing a dark field, but that is no expression. During the in situ hybridisation Proteinase K made 
some more digestion in the lens cells. There is no difference between sense and antisense slides. 
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4. Discussion 
 
 
In this study, a new BTB/POZ transcription factor was identified by sequencing and 
bioinformatics analyses, and validated and extended by genomic cloning and RT-PCR 
analysis. Sequence analysis of the murine Hic2 gene revealed that it represents the murine 
orthologues of the previously described human HIC2 gene (Deltour et al., 1999).  
The genomic organisations of human and mouse Hic2 are highly similar. They have strong 
sequence homologies (>80%) in their BTB/POZ and Zinc finger domains as well as in short 
peptide in their middle region (GLDLSK/K). HIC2 defines a subgroup of BTB/POZ domains 
unable to recur HDACs-containing (histone deacetylase) complexes (Deltour et al., 2001). 
The embryonic expression of Hic2 is in line with its human homologue HIC2 gene. The 
expression in  brain, embryonic ectoderm (neural plate, neural channel and neural tube), and 
lateral ventricul of olfactory lobe, showed that the gene seems to be involved in development 
of central and periphery nervous system. 
 
 
4.1 Hic2 Promoter and its binding sites 
 
The promoter was not predicted by the computer program PromoterInspector. It might be 
concluded that his activity is already low (second class promoter) but promoter activity might 
not be correlated with gene expression but could depend on with promoter hypermethylation 
which is often correlated with gene silencing. One hypothesis which could be tested new 
promoter activity to a consider gene function and determine if a hypermethylated gene is 
reactivated by demethylation. The next step should be transfection from the same deletion 
constructs in different cell lines (cancer and normal). 
MatInspector predicted some of the binding sites which could play a different role in Hic2 
promoter activity and gene expression. 
Transcription factors are modular proteins from functionally discrete domains and can be 
classified on the structure of the domain that binds DNA (Collins et al., 2001). Almost the 
entire Hic2 promoter binds sites GKLF1, Sp1, ZBP-89, AREB6, (Fig.4.1) coding the zinc 
finger domain and are involved in tumor and cancer genesis. 
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Figure 4.1 Positions of the some binding sites in distal part of Hic2 promoter. 1) Gutenriched Krüppel 
like factor, 2) Stimulating protein 1, 3) CCAAT box, 4) Zinc finger transcription factor ZBP-89, 
Wilms tumor suppressor, p53, 5) Atp1a1 regulatory element binding factor, 6) Glucocorticoid receptor 
 
The Hic2 share the same expression pattern with some of the transcription factors in its 
promoter: With Gut-enriched Krüppel-like factor (GKLF) it is epithelia cells of the 
gastrointestinal tract (Shields et al., 1996; Gareth-Sinha et al., 1996); With Ecotropic viral 
integration site 1 (Evil1) it is the peripheral nervous system (Hiroshi et al., 1999). 
ZBP-89 factor is interesting because of its expression which is known to be increased in 
gastric carcinoma cells (Ye et al., 1999). 
 
Nine Gut-enriched Krüppel-like factor binding sites are predicted between nucleotides -894 to 
-881, -884 to -871, -874 to -861, - 864 to -851, -841 to –854 to -841, -844 to -831, -834 to -
821, -819 to -806, and - 809 to -796. The gut-enriched Krüppel-like factor (GKLF) is a 
recently identified eukaryotic transcription factor that contains three C2H2 zinc fingers. The 
amino acid sequence of the zinc finger portion of GKLF is closely related to several Krüppel 
proteins, including the lung Krüppel-like factor (LKLF), the erythroid Krüppel-like factor 
(EKLF) and the basic transcription element binding protein 2 (BTEB2);(Shields and Yang 
1997). Expression of GKLF is enriched in epithelia cells of the gastrointestinal tract and in the 
epidermal layer of the skin (Shields et al., 1996; Gareth-Sinha et al., 1996). 
 
Nine Ecotropic viral integration site 1 encoded factor binding sites are predicted between 
nucleotides -894 to -878, -882 to -868, -872 to -858, -862 to - 848, -852 to - 838, -837 to -823, 
-827 to -813, -817 to -803, and -807 to -796. The Ecotropic viral integration site 1 Evil1 gene 
is thought to function as a transcription factor and a proto-oncogene for leukemia. Expression 
of the Evil1 gene was found in the renal tubules in the corticomedullary junction of the kidney 
and the cytoplasm of the developing oocytes in adult mice, fetal expression has been reported 
in urinary system, limb buds, heart, nasal pits, and bronchial epithelium. Additional 
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expression was observed in neural crest-derived cells associated with the peripheral nervous 
system and embryonic mesoderm (Hiroshi et al., 1999). 
 
One Stimulating protein 1 SP1, ubiquitous zinc finger transcription factor is predicted 
between nucleotides -793 to -781. Transcription factor SP1 is located in the nucleus of a 
mammalian cell and importantly related to expression of many cellular genes (Kuwahara et 
al., 2000). Sp1 is a ubiquitous, 778-amino acid transcription factor that recognizes GC-rich 
sequences present in many promoters (Azizkhan et al., 1993, Black et al., 1996). Although 
Sp1 has been viewed as a constitutive transcriptional activator which acts as a basal factor for 
TATAA-less promoters, an increasing number of studies indicate that Sp1-dependent 
transcription is regulated in response to a variety of signals. Sp1 expression is restricted to the 
brain (Adrian et al., 1999). Sp1-like proteins and Krüppel-like factors (KLFs) are highly 
related zinc-finger proteins that are important components of the eukaryotic cellular 
transcriptional machinery (Kaczynski et al., 2003).  
 
One cellular and viral CCAAT box is predicted between nucleotides -665 to -654. Cellular 
and viral CCAAT box is a promoter element common to all major histocompatibility complex 
class II genes (Dorn et al., 1987).  
 
One Zinc finger transcription factor ZBP-89 is predicted between nucleotides -406 to -395. 
Zinc-finger binding protein (ZBP-89, also known as BFCOL1, BERF-1 and ZNF-148) is a 
Krüppel-type zinc-finger transcription factor that binds to the same GC-rich sequences as Sp1. 
ZBP-89 expression is known to be increased in gastric carcinoma cells (Ye et al., 1999). Two 
zinc finger transcription families ZBP-89 and Sp1 regulate the gastrin promoter (Juanita, 
1984). 
  
One AREB6 (Atp1a1 regulatory element binding factor 6) is predicted between nucleotides –
209 to –201. The transcription factor AREB6 contains a homeodomain flankend by two 
clusters of Krüppel type C2H2. AREB6 binds to the E-box consensus sequence, CACCTGT, 
either the N- or the C-terminal zinc finger cluster (Ikeda et al., 1998). AREB6 is known to 
regulate the expression of the Na, K-ATPase α 1 subunit, interleukin 2 and δ-crystallin genes 
(Ikeda K., Kawakami K. 1995). 
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One Glucocorticoid receptor, C2C2 zinc finger protein binds glucocorticoid dependent to 
GREs is predicted between nucleotides -13 to -28. The glucocorticoid receptor (GR) belongs 
to the nuclear receptor (NRs) family. Most members of this family display an identical 
structural organization with an amino-terminal region A/B followed by a DNA-binding 
domain (DBD) consisting two zinc fingers (Moras et Gronemeyer, 1998). Activation of target 
genes relies in most cases on the ability of the GR to bind to specific DNA sequences named 
glucocorticoid responsive elements (GREs) (Mangelsdorf et al., 1995). Transcriptional 
repression of GREs has been linked to cell death (Rogatsky et al., 1999). 
 
All those transcriptions factors should play a role in the gene expression and promoter 
activity.  
 
 
4.2 Conserved domains 
 
The POZ domain and the zinc-finger region of the Murine Hic2, the human HIC2 and the 
chicken Gamma proteins are highly identical, thus suggesting that these proteins might exert 
similar functions. Comparison of the Murine Hic2 expression and that of a related gene in 
chicken γ, revealed some similarities, but also some differences. 
In comparison with other members of the HIC1 and HIC2 family (amino acid sequence 
identities), (Fig. 9), Hic2 showed more homology with HIC2 family members (human and 
zebra fish). Hic1 and Hic2 belong to the same BTB/POZ domain family, share the same 
domains (GLDLSK/K and Zinc finger 1-5) but expressions patterns are absolutely different. 
  
4.2.1 Hic2 BTB/POZ domain 
 
The BTB/POZ domain showed the highest identity with human and zebrafish homologue, and 
lowest with human HIC1 homologue. The POZ domain acts as a specific protein-protein 
interaction domain. This motif, found in a growing number of zinc finger proteins, can inhibit 
DNA binding and mediate dimerization (Bradwell et al., 1994). 
 
The characteristics of the family of genes to which Hic2 belongs are quite consistent with a 
role for the gene in developmental processes. Members of the POZ domain family of zinc-
finger transcription factors all possess a structure similar to that of Hic2, with highly 
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conserved N-terminal POZ domain and variable number of Krüppel –type zinc fingers 
towards the C-terminus (Bardwell and Treisman, 1994, Alibagli et al., 1995). 
 
The full- length Hic2 and Hic1 proteins share several functional properties and that’s why is 
for suspecting that their BTB/POZ domain heterodimerize. Heterodimer formation should 
show possible other DNA-binding specify and bind the other cofactors like homodimer. The 
BTB/POZ domain is not restricted to DNA-binding proteins or to other transcription factors 
but is likely to be a more general one. The BTB/POZ domain is involved in homodimer or 
heterodimer formation as well as oligomerization (Deltour et al., 2001). 
 
4.2.2 GLDLSKK/R polypeptide  
 
A short GLDLSKK/R polypeptide located in the central region between BTB/POZ domain 
and zinc fingers is perfectly conserved (Part 3 Fig.9 and 10). In this short polypeptide 
sequence Hic2 showed 100% identity with other Hic1 and Hic2 family members.  
This motif is highly related to the consensus PxDLSxK/R first identified in the C-terminal 
part of the E1A protein (Shaeper et al., 1992), and later in numerous transcriptional repressors 
in Drosophila and in vertebrates able to bind CtBP (C-terminal Binding Protein) corepressor. 
The invariant praline residue found in virtually all CtBP binding proteins is replaced by a 
Glycine residue in the Hic2 and Hic1 proteins (Part 3 Fig. 9 and 10). Founding of 
GLDLSKK/R motif in a region which is not well-conserved between Hic2 and Hic1 proteins 
from various species suggests that it can fulfil an important functional role. 
 
4.2.3 Hic2 zinc finger domain 
 
In comparison with the five  the zinc finger domains , Hic2 protein showed some differences 
with its mouse ortolog Hic1 and chicken γFBP protein(Part 3 Fig.10).  
The zinc finger 1-4 protein sequences showed more similarity between Hic1 and γFBP which 
seems to belong to the same protein subgroup of the Hic1 and Hic2 family members (Figure 
4.2). 
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                     ZF1                    ZF2 
Hic2         CIPCAKGFPSSEQLNAHVETH CSVCEKTYKDPATLRQHEKTH  
GammaFBP     CIPCGKGFPSSEQLNAHVEAH CSSCDKSYKDPATLRQHEKTH  
Hic1         CIPCGKGFPSSEQLNAHVEAH CASCDKSYKDPATLRQHEKTH  
 
                     ZF3                      ZF4                                      
Hic2         CNICGKMFTQRGTMTRHMRSHL CDECGMRFTRQYRLTEHMRVHS       
GammaFBP     CTICGKKFTQRGTMTRHMRSHL CDACGMRFTRQYRLTEHMRIHS       
Hic1         CTICGKKFTQRGTMTRHMRSHL CDACGMRFTRQYRLTEHMRIHS       
                    
                   ZF5 
Hic2          CQLCGGKFTQQRNLISHLRMH 
GammaFBP      CQVCGGKFAQQRNLISHMKMH 
Hic1          CQVCGGKFAQQRNLISHMKMH 
 
 
 
 
 
 
Figure 4.2 comparison of the zinc finger protein sequences between Hic2, Hic1 and γFBP. In the zinc 
finger 1 (ZF1) sequence it is two amino acids, for Hic2 it is one alanine (A), and for Hic1 and γFBP it 
is one glycine (G), one threonine (T) for Hic2 and one alanine (A) for Hic1 and γFBP.   In the zinc 
finger 2 (ZF2) sequence there are four amino acids, for Hic2 and  γFBP it is one serine (S), and for 
Hic1 one alanine (A), For Hic2 is one valine (V) and for Hic1 and γFBP serine (S), Hic2 coded one 
glutamic acid (E) and Hic1 and γFBP one asparatic acid (D) and finally for Hic2 is one threonine (T) 
and for Hic1 and γFBP serine (S). 
The sequences from first two zinc fingers showed more similarity between Hic1 and γFBP. 
In the zinc finger 3 (ZF3) sequence it are two amino acids, for Hic2 one asparagine (N), and for Hic1 
and γFBP one threonine (T), one methionine (M) for Hic2 and one lysine (K) for Hic1 and γFBP. Zinc 
finger four (ZF4) sequence showed two amino acids differences, for Hic2 is glutamic acid (E) and for 
Hic1 and γFBP one alanine (A), for Hic2 one valine (V) and for Hic1 and γFBP one isoleucine (I) on 
the same place. The last zinc finger five (ZF5) sequence showed differences in four amino acids. For 
Hic2 it is one threonine (T), and for Hic1 and γFBP is one alanine (A), than one leucine (L) in the case 
of Hic2 and one methionine (M) by Hic1 and γFBP, and at least one arginine (R) for Hic2 and one 
lysine (K) for Hic1 and γFBP  
 
 
Chicken has not γ-crystalline but the novel zinc finger proteins γFBP interact with the mouse 
γF-crystallin promoter and are expressed in the sclerotome during early somitogenesis. The 
expression of the murine γF-crystallin gene is most active at the beginning of lens fiber cell 
differentiation and that the level of expression gradually decreases during lens development. 
The increase in the levels of γFBP-B transcript and the transinhibitory effect of γFBP on 
promoters containing the γF-binding motiv, together with the gradual decline of γF-crystallin 
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gene expression during lens development, suggest that γFBP-B may play a physiological role 
in the regulation of  γF-crystallin gene expression (Liu et al., 1994).  
 
Becouse of the high similarity between Hic2 and γFBP zinc finger protein sequences it is 
possible that Hic2 bind on the γF-crystallin-promoter. The Hic2 expression in this work was 
not found on the eye (Fig. 3.21 B), seams to be that γF-crystallin in vivo not suppose to be 
target gene. 
 
4.3   Comparison of the Hic2 and Hic 1 expression patterns  
 
During embryonic development, Hic1 is expressed in the mesenchyme of the sclerotome, 
lateral body wall, limb and cranio-facial regions surrounding the outgrowing peripheral 
nerves during their differentiation. During fetal development, Hic1 additionally is expressed 
in mesenchymes apposed to precartilaginous condensations, at many interfaces to budding 
epithelia of inner organs, and weakly in muscles. Hic1 expression was observed in the 
embryonic anlagen of many tissues displaying anomalies in Miller-Dieker syndrome (MDS) 
patients (Grimm et al., 1999). 
 Hic2 and Hic1 genes share a three highly conserved domains but the expression pattern is 
different just like an exon-intron structure. Hic1 is expressed in somite derivatives and body 
wall of mouse embryos at TS17-20, in somite derivatives, epaxial and hypaxial mesenchymes, 
firstly, of the sclerotomes and later, also of the lateral body wall.  
Epaxial and hypaxial Hic1 expressions in these territories are sharply delineated against the 
non-expressing mesenchyme of the intercalated, central somite derivatives. Hic1 is also 
expressed in the limb anlagen, in cranio-facial regions and in mesenchymes associated with 
spinal ganglia, in mesenchymes surrounding peripheral nerves and limb anlagen at TS19-23, 
in mesenchymes surrounding cranial peripheral nerves, epithelial of the nose salivary glands 
and caudal pharyngeal pouches.  Hic1 is also expressed in the mesenchymes of a variety of 
inner organs, e.g. adrenal gland and metanephric kidney. During early cornea development, 
Hic1 is transiently expressed in a ring-shaped mesenchyme (Grimm et al., 1999). 
 
Because of the Hic2 expression in canallis centralis medullae spinalis, embryonic ectoderm 
(neural plate, neural channel and neural tube), and the lateral ventricle of the olfactory lobe, 
showed that gene seems to be involved in development of central and periphery nervous 
system (Fig. 15).  
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Hic1 expressing mesenchymal embed the developing peripheral nerves) suggesting a role for 
Hic1 in the specification of perineural mesenchymes from the earliest stages of peripheral 
nervous system (PNS) development (Grimm et al., 1999).  
 
Hic1 and Hic2 might share expression territories in the sclerotome, head mesenchyme, 
vertebral arch and rib associated mesenchymes and both could have a similar function in 
peripheral nervous system. Hic2 is expressed in the limbic region of the brain olfactory lobe 
(Fig. 16). There might be share expression territories in the head where Hic1 is activated in 
the embryonic anlagen of some tissues affected in MDS (Miller Diecker syndrome) patients. 
Hic2 showed expression in the small intestine caecum, duodenum, jejunum (Fig.3.18).  
 
4.4 Hic2 and its avian homologue γFBP 
 
γFBP and Hic2 might share expression territories in the sclerotome, head mesenchyme, 
urogenital ridge, intestine, vertebral arch and rib associated mesenchymes. However, any 
expression of the Murine Hic2 gene in lenses at embryonic, fetal stages by means of ISHs of 
whole embryos and on paraffin sections was not detected (Fig. 3.21 B). Thus, it is not likely 
that the Murine Hic2 gene is implicated in lens differentiation.  
 
4.5 Hic2 exonic CpG islands  
 
The increased stringency also substantially reduced the number of exonic CpG islands. The 
biological functions of these islands are not well understood, but CpG islands located in 
nonpromoter regions can play significant roles in gene regulation, they also seem to be 
frequent targets for de novo methylation in cancer and aging. Therefore, although the 
increased stringency preferentially locates CpG islands in the 5′ regions of genes, it may also 
result in the loss of smaller regions of DNA from the data set that may be functionally 
important in gene control (Takai and Jones, 2002). 
 
HIC1 (hypermethylated in cancer) is a candidate tumor suppressor gene identified because of 
its association with a “CpG” island at 17p13.3 that is aberrantly hypermethylated and 
transcriptionaly inactivated in several common types of human cancer (Makos-Wales et al., 
1995).  
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By regulating the expression of a large number of genes that have GC-rich promoters may 
take part in virtually all facts of cellular function, including cell proliferation, apoptosis, 
differentiation, and neoplastic transformation (Kaczynski et al., 2003).  
The role of promoter hypermethylation, an epigenetic alteration, has been associated with the 
silencing of tumor suppressor genes in human cancer; HIC1 promoter methylation was 
frequently seen in association with microsatellite instability in carcinoma of cervix uteri. 
Promoter methylation was associated with gene silencing in cervical cancer (CC) cell lines. 
HIC1 (18.3%) genes were less frequently methylated in primary tumors.  
The HIC1 gene was methylated in 5 of 8 cell lines. Three of the methylated cell lines (C-4I, 
SiHa, and ME-180) and one of the three unmethiylated cell lines (MS751) showed down 
regulated expression. Treatment with 5-Aza-2' deoxycytidine or n-butyrate alone or the 
combination of both activated gene expression in all the cell lines, whether or not promoter 
had detectable methylation (Narayan et al., 2003). 
 
4.6 Hic2 a candidate for tumor suppressor gene? 
 
For a better understanding of the potential role of Hic2 as a possible candidate for tumor 
suppressor gene two binding sites with tumor suppressor genes associated with human tumors 
are important, p53 (numerous cancers) and Wilms tumor suppressor WT1( kidney). Two 
Wilms Tumor Suppressor binding sites are predicted between nucleotides +405 to +393 and -
790 to – 778. One tumor suppressor p 53 is predicted between nucleotides –734 to -715. Are 
they direct involved in Hic2 activity could be next important examination of the promoter 
region. 
 
SAGE Brain Anatomic Viewer Results, The Cancer Genome Anatomy Project (CGAP) 
showed that HIC2 involved in different carcinoma of the brain which are located in the 
cerebrum and cerebellum: oligodendroglioma, glioblastoma, grade II astrocytoma, grade I 
astrocytoma, ependymoblastoma, ependymoma (Fig.4.3). 
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Figure 4.3 SAGE Brain Anatomic Viewer Results, The Cancer Genome Anatomy Project (CGAP) 
results during the analysis of cancer tissue and cell lines. Different carcinoma types located in the 
cerebrum and cerebellum, (agenda is on the left side). 
 
 
 
Vertebrate DNA is generally depleted in the dinucleotide CpG; it has recently been shown 
that some vertebrate genes contain CpG islands, regions of DNA with a high G+C content and 
a high frequency of CpG dinucleotide relative to the bulk genome. Possible functions of CpG 
islands in transcriptional and post-transcriptional regulation of gene expression were related to 
theories for the maintenance of CpG islands as "methylation-free zones" in germline DNA 
(Gardiner, Fromer 1987). 
For example the HIC1 (hypermethylated in cancer) is a candidate tumor suppressor gene 
identified because of its association with a “CpG”island at 17p13.3 that is aberrantly 
hypermethylated and transcriptionaly inactivated in several common types of human cancer 
(Makos-Wales et al., 1995).  
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By regulating the expression of a large number of genes that have GC-rich promoters may 
take part in virtually all facts of cellular function, including cell proliferation, apoptosis, 
differentiation, and neoplastic transformation (Kaczynski et al., 2003).  
Database searches identified on chromosome 22q11.2 in a region subject to translocation and 
also known as BCRL-2 (Breakpoint Cluster Region-Like 2), Mitellman break point, in this 
region are mapped some of the genes involved in tumor and cancer genesis (Dunham et al., 
1999).  
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5. Summary 
 
5.1 Analysis and characterization of the mouse Hic2 gene 
  
Like Hic1 and γFBP (chicken), Hic2 cDNA coded five Krüppel-type C2H2 zinc finger 
domain. Through the sequencing and comparation with different protein sequences from the 
homolog proteins from different species (HIC1, Hic1, HIC2, γFBP, and Hypothetical protein), 
Hic2 protein shares more than 80% homology with HIC1 through the BTB/POZ and zinc 
finger domains, and both proteins have identical GLDLSKK/R motifs.  
 
A new part of Hic2 gene coding, exon two, and new exon one deduced full-length Hic2 
protein contains 601 amino acids. Hic2 gene has two Exons (240 and 1842 bp), with one 
Intron (2182 bp). 
 
The location of the gene is mouse chromosome 16 (B1, UniGene Cluster Mm.103787 Mus 
musculus). The human gene HIC2 maps to chromosome 22q11.2, and is a homolog of the 
HIC1 candidate tumor suppressor gene located at 17p 13.3. (Deltour et al. 2001). 
 
Upstream from the TATA box MatInspector predicted different transcription binding sites. 
Between them Wilms Tumor Suppressor and p53 are most interesting transcription sites for 
the Hic2 gene. That’s why the Hic2 promoter activity was checked. 
 A 1.2 kb promoter fragment of Hic2 has been characterized in a gene reporter assay system. 
The peak activity of the Hic2 promoter is associated with the total fragment, the next higher 
activity is in the fragment which included Wilms Tumor Suppressor and p53 transcription 
sites. 
The expression of the mouse Hic2 was investigated by in situ hybridisations (ISHs) of whole 
mount embryos and paraffin sections. Hic2 expression was detected in restricted territories of 
the brain, sinus centralis, olfactory bulb, canallis centralis medullae spinalis, embryonic 
ectoderm (neuroepithelium of neural tube), and small intestine.  
Because of its expression in the central nervous system, and mapping position of its human 
homolog HIC2, Hic2 could be involved in some syndromes. Patients with a 22q11 deletion 
have disrupted brain development which may involve abnormal neural crest cell migration, 
(Van Amelsvoort et al., 2001). It is now recognized that the 22q11.2 deletion syndrome 
encompasses the phenotypes previously described as DiGeorge syndrome (DGS) and 
velocardiofacial syndrome (Shprintzen syndrome),(Thomas and Graham 1997). 
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5. Zusammenfassung 
 
Die cDNA des Hic2-Gens kodiert wie Hic1 und γFBP (Huhn) ebenfalls fünf C2H2 Zink-
Finger des Krüppel-Typs. Im Vergleich der ermittelten Hic2-Sequenz mit verschiedenen 
Proteinsequenzen homologer Proteine aus verschiedenen Spezies (HIC1, Hic1, HIC2, γFBP, 
sowie ein hypothetisches Protein) zeigt Hic2 über 80% Homologie zu HIC1 im Bereich der 
BTB/POZ- und Zink-Finger-Domänen. Darüber hinaus besitzen beide Proteine identische 
GLDLSKK/R-Motive. 
   
Innerhalb dieser Arbeit wurde ein neuer Bereich des ersten und zweiten kodierenden Exons 
von Hic2 charakterisiert. Die kodierende Sequenz wurde vollständig bestimmt. Das 
vollständig abgeleitete Hic2-Protein besteht aus 601 Aminosäuren. Das Hic2-Gen enthält 
zwei Exons (240 bp und 1842 bp) und ein Intron von 2182 bp. 
   
Hic2 ist auf dem Maus-Chromosom 16 lokalisiert (B1, UniGene Cluster Mn. 103787 Mus 
musculus). Das menschliche HIC2-Gen liegt auf dem Chromosom 22q11.2. Es ist zu HIC1, 
einem auf 17p 13.3 lokalisierten Tumor-Suppressor Kandidaten-Gen, homolog (Deltour et al. 
2001).  
Stromaufwärts der TATA-Box wurden durch MatInspector verschiedene Tranksriptions-
Bindestellen identifiziert. Hierbei stellen der Wilms Tumor-Suppressor sowie p53 die 
interessantesten Transkriptionsstellen des Hic2-Gens dar. Aus diesem Grund wurde die Hic2-
Promotoraktivität überprüft. Ein 1.2 kb großes Promotorfragment von Hic2 wurde in einem 
Gen-Reporter Nachweissystem charakterisiert. Die größte Promotoraktivität zeigte sich mit 
dem vollständigen, undeletierten Fragment, gefolgt von der Aktivität des Fragments zwei, 
welches die Wilms Tumor-Suppressor- und p53-Transkriptionsstellen enthält. Dies deutete 
auf eine mögliche funktionelle Bedeutung dieser Bereiche für die Hic2-Expression hin.  
 
Die Expression des Hic2-Gens der Maus wurde mit Hilfe von in situ Hybridisierungen (ISHs)  
auf ganzen Embryonen und Paraffin-Schnitten untersucht. Eine Hic2-Expression wurde in 
abgegrenzten Regionen des Gehirns, sinus centralis, Riechkolbens, canallis centralis medullae 
spinalis, embryonalen Ektoderms (Neuroepithelium des Neuralrohrs), und des Dünndarms 
detektiert. Aufgrund seiner Expression im zentralen Nervensystem sowie der durch 
Kartierung bestimmten Lokalisation des homologen menschlichen HIC2 könnte Hic2 an 
einigen durch Deletionen verursachte Syndrome beteiligt sein. Einige Befunde lieferten 
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Beweise, dass Personen mit einer 22q11-Deletion unter einer unvollständigen 
Gehirnentwicklung leiden, die eine abnormale Wanderung von Zellen der Neuralleiste 
beinhalten könnte (Van Amelsvoort et al., 2001). Mittlerweile ist bekannt, dass das 22q11.2 
Deletionssyndrom mit den früher beschriebenen Phänotypen des DiGeorge-Syndroms (DGS) 
sowie des velokardiofaziales Syndroms (Shprintzen-Syndrom) in Verbindung steht (Thomas 
and Graham 1997). 
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9. Apendix 
Abbreviations 
 
AA        amino acid                                                               LB          Luria-Broth 
AP        alkaline Phosphatase                                                m            meter 
ATP      adenosinetriphosphate                                             M            mol 
Bp         base pare                                                                 MAB       Maleic acid buffer 
BTB      Protein-protein-interactions-Domain,                    MDS        Miller-Dieker-Syndrome   
             For Broad complex, tramtrack,                               ME          Mercaptoethanol   
             Bric a brac, too POZ or ZIN                                   min          minutes 
°C        Celsius degree                                                          N.            nervus 
cDNA    complementary DNA                                            NTP         Nucleosidtriphosphate 
CTP       Cytosinetriphosphate                                             32P           Phosphorisotope 
dATP     Desoxyadenosinetriphosphate                               PAA       Polyacrilamide  
dCTP      Desoxycytosinetriphosphate                                  PBS       Phosphate buffered saline 
DEPC     Diethylpyrocarbonate                                            p.c.         post coitum    
dGTP      Desoxyguanosinetriphosphate                               PCR       Polymerase Chain Reaction 
Dig          Dioxigenin (Steroid from Digitalis purpurea)     PFA        Paraformaldehyde 
DNA        Desoxyribonucleicacid                                        PN          Phosphat-Nonident P40 buffer 
DTT         Dithioerythriol                                                    POZ        Protein-protein interaction                         
dTTP        Desoxythymidintriphosphate                                            domain, for Poxvirus or zinc        
dNTP        Desoxyribonukleosidtriphosphate                     RNA       Ribonucleicacid 
ddNTP      Didesoxyribonukleosidtriphosphate                  rpm         rotations per minute 
dpc            days post coitum                                                SDS        Sodium dodecyl sulphate 
EDTA       Ethylendiamintetraacetate                                  sec           seconds 
EST          Expressed sequence  tag                                     SSC         Sodium chloride-sodium citrate 
FA            Formamide                                                         TAE         Tris-Acetate-EDTA buffer 
G               Gramm                                                               TBE          Tris-Borat-EDTA buffer 
GTP            Guanosinetriphosphate                                     TBS          Tris buffered saline                                                
IDG             Institute for development genetic                     TE             Tris-EDTA 
ISH              in situ Hybridisation                                         TS             Theiler stadium 
IPTG           Isopropyl-β-D-thio-Galactopyranosid             Tris           Tri(hydroxymethyl)aminomethan 
K                 kilo                                                                   U               Unit                                                                       
Kb               kilobasepare                                                     UTP           Uraciltriphosphate  
L                  liter                                                                
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Some gene names abbreviations: 
 
  En1          Engrailed 1 
 Evil1         Ecotropic viral integration site 1 
γFBP          γF-crystalline binding protein 
HIC1          Hypermethilated in Cancer 1 
Hic2           Hypermethilated in Cancer 2 
OVCA2       Ovarian Cancer 2 
WT1            Wilms tumor suppressor 
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